verapamil has been researched along with Auricular Fibrillation in 377 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The VERDICT (Verapamil Versus Digoxin and Acute Versus Routine Serial Cardioversion Trial) is a prospective, randomized study to investigate whether: 1) acutely repeated serial electrical cardioversions (ECVs) after a relapse of atrial fibrillation (AF); and 2) prevention of intracellular calcium overload by verapamil, decrease intractability of AF." | 9.12 | Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. ( Bosker, HA; Crijns, HJ; Hemels, ME; Ranchor, AV; Van den Berg, MP; Van Gelder, IC; Van Noord, T; Van Veldhuisen, DJ; Veeger, NJ; Wiesfeld, AC, 2006) |
| "100 consecutive patients with atrial fibrillation (AF) of at least four weeks' duration and indications for cardioversion were assigned randomly to two groups, one treated with verapamil (verapamil group) and the other with digoxin (digoxin group) before cardioversion." | 9.11 | Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil. ( Edvardsson, N; Firsovaite, V; Fredholm, O; Kronvall, T; Lindholm, CJ; Meurling, CJ; Möller, SJ; Olsson, SB; Pettersson, T; Platonov, PG; Roijer, A, 2004) |
| "While verapamil has been proposed as a treatment for reducing electrophysiological remodeling due to atrial fibrillation and atrial tachyarrhythmias, no previous study has tested its effects in brady-tachy patients implanted with a dual-chamber pacemaker." | 9.11 | A controlled study on the effect of verapamil on atrial tachycaarrhythmias in patients with brady-tachy syndrome implanted with a DDDR pacemaker. ( Bertaglia, E; Biffi, M; Boriani, G; Branzi, A; Carboni, A; Latini, R; Martignani, C; Sciotto, F, 2005) |
| "Verapamil and ibutilide blunt the atrial fibrillation-induced shortening of atrial refractoriness that may predispose to an immediate recurrence of atrial fibrillation after cardioversion." | 9.10 | Comparison of verapamil and ibutilide for the suppression of immediate recurrences of atrial fibrillation after transthoracic cardioversion. ( Knight, BP; Morady, F; Oral, H; Ozaydin, M; Pelosi, F; Sticherling, C; Strickberger, SA; Tada, H, 2002) |
| "The aim of this prospective, randomized study was to investigate the effect of pretreatment with two different intracellular calcium-lowering drugs (verapamil and metoprolol) on recovery from atrial effective refractory period (AERP) shortening after internal electrical cardioversion (EC) of persistent atrial fibrillation (AF) in patients on amiodarone." | 9.10 | Effects of verapamil and metoprolol on recovery from atrial electrical remodeling after cardioversion of long-lasting atrial fibrillation. ( Bertaglia, E; D'Este, D; Michieletto, M; Pascotto, P; Zerbo, F, 2003) |
| "To evaluate the impact, on atrial fibrillation (AF) recurrences, of verapamil addition to a class IC or III antiarrhythmic drug in patients, with persistent AF, who underwent an electrical cardioversion (EC)." | 9.10 | VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). ( Alfano, F; Campana, A; Canciello, M; De Fabrizio, G; De Matteis, C; De Pasquale, M; De Simone, A; Di Mauro, M; Manzo, M; Sabino, L; Stabile, G; Turco, P; Vitale, DF, 2003) |
| "To evaluate, in a prospective and randomized fashion, the efficacy of a pretreatment with verapamil (V) in reducing recurrences of atrial fibrillation (AF) after electrical cardioversion (C)." | 9.09 | Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. ( De Matteis, C; De Simone, A; Di Napoli, T; Di Stasio, M; Gasparini, M; Petrazzuoli, F; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 1999) |
| "The purpose of this study was to assess the effect of verapamil on immediate recurrences of atrial fibrillation occurring after successful electrical cardioversion." | 9.09 | Effect of verapamil on immediate recurrence of atrial fibrillation. ( Augostini, R; Daoud, EG; Hummel, JD; Kalbfleisch, SJ; Williams, S, 2000) |
| "Racemic (R /S)- verapamil is widely used in the management of chronic atrial fibrillation." | 9.09 | Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. ( Busse, D; Drescher, S; Eichelbaum, M; Fromm, MF; Kühlkamp, V; Mörike, K, 2001) |
| "The role of verapamil in the prevention of atrial fibrillation (AF) in patients with recurrent AF is unknown." | 9.09 | Effect of verapamil on prevention of atrial fibrillation in patients implanted with an implantable atrial defibrillator. ( Ayers, GM; Lau, CP; Tse, HF; Wang, Q; Yu, CM, 2001) |
| "The role of digoxin and verapamil in the control of ventricular response in rapid atrial fibrillation is well established." | 9.09 | Clinical assessment of clonidine in the treatment of new-onset rapid atrial fibrillation: a prospective, randomized clinical trial. ( Abdollah, H; Ghali, WA; Moritz, S; Sanfilippo, AJ; Simpson, CS, 2001) |
| "Atrial fibrillation occurred in 15% of the patients receiving placebo and in 8% of the patients receiving verapamil (difference not significant)." | 9.08 | Verapamil as prophylactic treatment for atrial fibrillation after lung operations. ( Demedts, M; Demuynck, K; Deneffe, G; Lacquet, L; Tits, G; Tjandra-Maga, T; Van Mieghem, W, 1996) |
| "To determine the relative effectiveness of a verapamil-quinidine sequential combination versus digoxin-quinidine in the emergency department treatment of paroxysmal atrial fibrillation (PAF)." | 9.08 | Effectiveness of verapamil-quinidine versus digoxin-quinidine in the emergency department treatment of paroxysmal atrial fibrillation. ( Dillon, EC; Innes, GD; Metcalfe, C; Vertesi, L, 1997) |
| "In a placebo-controlled study the effects on ventricular rate regulation and exercise performance of xamoterol, 100 mg two times a day and 200 mg two times a day, and slow-release verapamil, 240 mg once a day, were assessed in 21 patients with chronic atrial fibrillation." | 9.07 | Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation. ( Lundström, T; Moor, E; Rydén, L, 1992) |
| "Efficacy and safety of intravenous flecainide (2 mg/kg body weight in 10 minutes), verapamil (10 mg in 1 minute), and propafenone (2 mg/kg body weight in 10 minutes) were investigated in 90 consecutive patients with atrial fibrillation (AF) or flutter (AFL)." | 9.07 | Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. ( Kingma, JH; Suttorp, MJ, 1992) |
| "In 69 consecutive patients with recent-onset atrial fibrillation, we compared the usefulness of verapamil, flecainide and propafenone for the acute conversion to sinus rhythm within 1 hour of the start of intravenous infusion." | 9.06 | Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm. ( Kastrati, A; Kondili, A; Popa, Y, 1990) |
| "In an open clinical trial, the therapeutic effect of sustained-release verapamil hydrochloride was investigated in 40 patients with chronic atrial fibrillation." | 9.06 | [Delayed-release verapamil hydrochloride in chronic atrial fibrillation. Reducing the heart rate]. ( Gonska, BD; Wiedey, KD, 1990) |
| "The effects of two calcium channel blockers, diltiazem (270 mg/day) and verapamil (240 mg/day), were studied in 18 patients with chronic atrial fibrillation." | 9.06 | Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. ( Lundström, T; Rydén, L, 1990) |
| "In a single-blind randomized study, the efficacy of intravenous flecainide (2 mg/kg/10 minutes) versus verapamil (10 mg/1 minute) was assessed in 40 patients with paroxysmal atrial fibrillation (AF) or atrial flutter (AFI)." | 9.06 | Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. ( Kingma, JH; Lie-A-Huen, L; Mast, EG; Suttorp, MJ, 1989) |
| "The effects of esmolol, an ultrashort-acting beta blocker, and verapamil were compared in controlling ventricular response in 45 patients with atrial fibrillation or atrial flutter, in a randomized, parallel, open-label study." | 9.06 | Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. ( Das, G; Michelson, EL; Platia, EV; Porterfield, JK, 1989) |
| "This study has compared the effect on heart rate control of the addition of pindolol 15 mg bd or verapamil 40 mg tds to maintenance digoxin therapy in 12 patients with chronic atrial fibrillation." | 9.06 | Improved control of atrial fibrillation with combined pindolol and digoxin therapy. ( Channer, KS; James, MA; Papouchado, M; Rees, JR, 1989) |
| "It has been suggested that patients in whom atrial fibrillation (AF) is associated with poor exercise tolerance respond better to treatment with xamoterol plus digoxin than to digoxin alone; this may be attributable to better control of exercise induced tachycardia." | 9.06 | Factors affecting the clinical response to treatment with digoxin and two calcium antagonists in patients with atrial fibrillation. ( Lewis, RV; McDevitt, DG, 1988) |
| "Six patients with chronic atrial fibrillation (AF) took single doses of digoxin, verapamil and diltiazem, alone and in combination." | 9.06 | Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. ( Irvine, N; Lewis, RV; McDevitt, DG, 1988) |
| " The efficacy of verapamil alone, or in combination with digoxin, was compared with digoxin alone in eight patients with chronic atrial fibrillation in this double-blind placebo-controlled study." | 9.06 | Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation. ( Beasley, CR; Challenor, V; Holgate, ST; Pomfret, SM, 1988) |
| "Twelve patients (including 2 females) with chronic atrial fibrillation were entered into a randomized, double blind crossover study to compare the effects of digoxin and verapamil upon heart rate, exercise tolerance and symptom control." | 9.06 | A comparison of verapamil and digoxin in the treatment of atrial fibrillation. ( Lakhani, M; Lewis, R; McDevitt, DG; Moreland, TA, 1987) |
| "The efficacy and safety of oral verapamil, 240 mg, with or without digoxin were studied in 52 patients with chronic atrial fibrillation at rest, and during mild and maximal exercise." | 9.05 | Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. ( David, D; Di Segni, E; Guerrero, J; Kaplinsky, E; Klein, HO; Lang, R; Levy, A; Sareli, P; Weiss, E, 1983) |
| "The safety and efficacy of oral verapamil to control exercise tachycardia in 27 patients with atrial fibrillation and 3 with atrial flutter receiving digitalis was evaluated in a double-blind, randomized, crossover study." | 9.05 | Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis. ( Baessler, C; Morganroth, J; Panidis, IP, 1983) |
| "Hemodynamic effects of the beta-receptor-blocking agent metoprolol (100 mg orally) and the calcium antagonist verapamil (160 mg orally) were analyzed in 24 patients with atrial fibrillation of different etiology (idiopathic atrial fibrillation, 6 cases; congestive cardiomyopathy, 6 cases; mitral stenosis, 5 cases; mitral regurgitation, 6 cases)." | 9.05 | [Modification of hemodynamics in tachycardiac atrial fibrillation by metoprolol and verapamil]. ( Bilgin, Y; Gigler, G; Maier, WD; Neuss, H; Schlepper, M; Thormann, J, 1983) |
| "The safety and efficacy of the intravenous (IV) calcium channel blocker, verapamil, in controlling the ventricular response or converting to sinus rhythm patients with atrial flutter or atrial fibrillation were assessed." | 9.05 | Atrial fibrillation and flutter. Immediate control and conversion with intravenously administered verapamil. ( McDonough, T; Parker, M; Talano, JV; Tommaso, C, 1983) |
| "Fourteen patients with onset of atrial fibrillation (11) or flutter (three) and ventricular rate over 120 beats per minute following cardiac surgery were treated with intravenous (IV) doses of verapamil hydrochloride or placebo in a double-blind crossover protocol." | 9.05 | Double-blind crossover randomized trial of intravenously administered verapamil. Its use for atrial fibrillation and flutter following open heart surgery. ( Danoviz, J; Gunnar, RM; Hwang, MH; Loeb, HS; Pacold, I; Rad, N, 1984) |
| "Oral verapamil has previously been shown to reduce heart rate at rest and during mild exercise in chronic atrial fibrillation." | 9.05 | Verapamil improves exercise capacity in chronic atrial fibrillation: double-blind crossover study. ( David, D; Di Segni, E; Gefen, J; Guerrero, J; Kaplinsky, E; Klein, HO; Lang, R; Libhaber, C; Sareli, P; Weiss, E, 1983) |
| "We evaluated the effectiveness of oral verapamil therapy for control of ventricular rate in digitalized patients with atrial fibrillation (AF) with three clinical problems: chronic AF with rapid rate at rest (four patients), chronic AF with accelerated rate during modest exercise (five patients), and rapid rates during paroxysmal AF (four patients)." | 9.05 | Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation. ( Guerrero, J; King, BD; Pitchon, R; Schneider, RR; Stern, EH; Wiener, I, 1982) |
| "The effectiveness of verapamil in controlling ventricular rate was evaluated in 20 patients with atrial fibrillation or flutter with a rapid ventricular response (Group 1) and 30 patients with paroxysmal supraventricular tachycardia (Group 2)." | 9.05 | Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study. ( Appel, R; Myerburg, RJ; Sung, RJ; Waxman, HL, 1981) |
| "The comparative effects of diltiazem and verapamil in 30 patients with long-standing atrial fibrillation were evaluated in a prospective clinical trial." | 9.05 | Diltiazem, verapamil, and quinidine in patients with chronic atrial fibrillation. ( Anda, L; Eichelbaum, M; Greenblatt, DJ; Ochs, HR, 1985) |
| "A double-blind randomized study was performed to compare the efficacy of intravenous verapamil with saline in 28 patients with a rapid ventricular rate and atrial fibrillation or atrial flutter." | 9.04 | Verapamil in atrial fibrillation and atrial flutter. ( Aronow, WS; Ferlinz, J; Karlsberg, RP; Landa, D; Plasencia, G; Wong, R, 1979) |
| " Verapamil remains the most widely used calcium antagonist for the treatment of cardiac arrhythmias." | 8.76 | Verapamil in cardiac arrhythmias: an overview. ( Vohra, J, 1982) |
| "It is clear from clinical and experimental data that have been reported thus far that verapamil is highly effective in the therapy of cardiac arrhythmias, and that it acts by a different mechanism than most of the commonly used antiarrhythmic drugs." | 8.75 | Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil. ( Hoffman, BF; Rosen, MR; Wit, AL, 1975) |
| "In the JADER analysis, hemorrhage was significantly associated with treatment with edoxaban and verapamil (reporting odds ratio = 1." | 8.31 | Association between hemorrhage and direct oral anticoagulants in combination with verapamil: Analysis of Japanese Adverse Drug Event Report database and electronic medical record data. ( Hosomi, K; Komatsu, Y; Takegami, M; Yodoshi, M; Yokoyama, S, 2023) |
| " We herein report an elderly patient with CKD who suffered bradycardia shock after the combined use of carteolol eye drops and verapamil for glaucoma and paroxysmal AF." | 8.02 | Bradycardia Shock Caused by the Combined Use of Carteolol Eye Drops and Verapamil in an Elderly Patient with Atrial Fibrillation and Chronic Kidney Disease. ( Akutsu, N; Arai, R; Fukamachi, D; Monden, M; Murata, N; Okumura, Y, 2021) |
| " Verapamil hydrochloride and diltiazem hydrochloride are combined P-glycoprotein (P-gp) and CYP3A4 inhibitors and may be associated with increases in the risk of bleeding with DOACs." | 7.96 | Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function. ( Brown, JD; Lesko, L; Lip, GYH; Pham, P; Schmidt, S, 2020) |
| "Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients." | 7.96 | Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. ( Bahteeva, D; Bochkov, P; Cherniaeva, M; Golovina, O; Gorbatenkova, S; Kulikova, M; Mirzaev, K; Ostroumova, O; Rytkin, E; Shevchenko, R; Sychev, D, 2020) |
| "Simvastatin (SV) leads to reduction of ventricular rhythm during atrial fibrillation on rabbit atrioventricular (AV) nodes." | 7.81 | Acute effects of simvastatin to terminate fast reentrant tachycardia through increasing wavelength of atrioventricular nodal reentrant tachycardia circuit. ( Alizadeh, AM; Aminolsharieh Najafi, S; Khori, V; Moheimani, HR; Nayebpour, M; Shakiba, D; Zahedi, M, 2015) |
| "There is evidence that verapamil promotes the persistence of paroxysmal atrial fibrillation (AF)." | 7.76 | Verapamil eliminates the hierarchical nature of activation frequencies from the pulmonary veins to the atria during paroxysmal atrial fibrillation. ( Hasebe, H; Kamiya, K; Kodama, I; Kuroda, Y; Kushiyama, Y; Osaka, T; Yokoyama, E, 2010) |
| " To study the possible role of EAD in spontaneous initiation of atrial fibrillation (AF), we tested the effects of L-type Ca(2+) channel blocker verapamil in canine models of cholinergic-dependent AF." | 7.72 | [Effects of verapamil on atrial fibrillation spontaneous initiation in the intact canine heart]. ( Beloshapko, GG; Fedorov, VV; Glukhov, AV; Iushmanova, AV; Rozenshtraukh, LV; Sharifov, OF, 2003) |
| "To assess effect of calcium antagonists amlodipine and verapamil on the risk of development of atrial fibrillation after coronary artery bypass surgery." | 7.72 | [Effect of calcium antagonists verapamil and amlodipine on the risk of development of atrial fibrillation after coronary artery bypass grafting]. ( Afanas'ev, SA; Akhmedov, ShD; Antonchenko, IV; Dzhavadova, GK; Evtushenko, AV; Kandinskiĭ, ML; Kozlov, BN; Popov, SV; Shipulin, VM; Vecherskiĭ, IuIu, 2003) |
| "5-Fluorouracil, a widely used drug in cancer treatment, is known to have cardiotoxic effects: chest pain with ECG changes, arrhythmias, arterial hypertension or hypotension, myocardial infarction, cardiogenic shock and sudden death have been described in the literature." | 7.72 | Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases. ( Alberti, A; Corrada, E; Ferrari, S; Mafrici, A; Marenna, B, 2003) |
| "The objective was to assess the effect ofverapamil on atrial fibrillation (AF) cycle length and spatial dispersion of refractoriness in patients with chronic AF." | 7.71 | Increased dispersion and shortened refractoriness caused by verapamil in chronic atrial fibrillation. ( de Bakker, JM; Elvan, A; Hauer, RN; Ramanna, H; Robles de Medina, EO; Wittkampf, FH, 2001) |
| "We present a case report describing an interaction between topical timolol maleate, verapamil, and flecainide resulting in symptomatic bradycardia." | 7.71 | Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report. ( Herd, A; Minish, T, 2002) |
| "Verapamil is an effective drug to slow ventricular rate in atrial fibrillation (AF)." | 7.70 | Verapamil prolongs atrial fibrillation by evoking an intense sympathetic neurohumoral effect. ( Dai, CP; Friedman, HS; Hussain, A; Mallipeddi, D; Rodney, E; Sharafkhaneh, A; Sinha, A; Sinha, B; Wattanasuwan, N; Win, M, 1999) |
| "The aim of our study was to verify the effect of oral administration of verapamil on atrial electrophysiologic characteristics after cardioversion of persistent atrial fibrillation (AF) in humans." | 7.70 | Postcardioversion atrial electrophysiologic changes induced by oral verapamil in patients with persistent atrial fibrillation. ( Bianconi, L; Calò, L; Castro, A; Gentilucci, G; Lamberti, F; Pandozi, C; Santini, M; Scianaro, MC, 2000) |
| "Electrical remodelling with shortening of the atrial refractory period and increased fibrillatory rate occurs after onset of atrial fibrillation and can be attenuated by pre-treatment with intravenous verapamil." | 7.70 | Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil. ( Carlson, J; Ingemansson, MP; Lindholm, CJ; Meurling, CJ; Olsson, SB; Roijer, A; Smideberg, B; Sornmo, L; Stridh, M, 1999) |
| "The antiarrhythmic properties of sublingual verapamil were investigated in seven patients with acute fast atrial flutter (n = 2) or fibrillation (n = 5)." | 7.69 | Preliminary investigation of the efficacy of sublingual verapamil in the management of acute atrial fibrillation and flutter. ( Fort, S; John, DN; Lewis, MJ; Luscombe, DK, 1994) |
| "Atrial contractile dysfunction after short-term atrial fibrillation is reduced by the calcium antagonist verapamil, which suggests that transsarcolemmal calcium influx contributed to this dysfunction." | 7.69 | Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. ( Aksnes, G; Christensen, G; Leistad, E; Verburg, E, 1996) |
| "We studied retrospectively 102 patients, 76 males, 26 females, mean age 56 +/- 12 years, with paroxysmal or sustained atrial fibrillation or atrial flutter (AFlut) treated with verapamil/quinidine (Cordichin) (dosage 3 to 5 times 1 tablet/day)." | 7.69 | [Conversion rate and prevention of recurrence of paroxysmal and sustained atrial fibrillation or atrial flutter with verapamil/quinidine]. ( Pfitzner, P; Trappe, HJ, 1996) |
| "Verapamil is used to control ventricular response during atrial fibrillation (AF)." | 7.68 | Effects of verapamil on electrophysiological properties in paroxysmal atrial fibrillation. ( Arakawa, K; Hamasaki, N; Kumagai, K; Matsuo, K; Moroe, K; Ono, M; Yamanouchi, Y, 1993) |
| "The aim was to evaluate the effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation." | 7.68 | Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. ( Haraguchi, M; Kusukawa, R; Matsuda, M; Matsuda, Y; Tada, T; Takahashi, T; Yamagishi, T, 1991) |
| "The Authors report a case of incessant torsade de pointes, associated with QT prolongation, due to the proarrhythmic effect of quinidine, which was successfully treated with i." | 7.68 | [Torsade de pointes induced by quinidine: a case treated successfully with verapamil]. ( Arfiero, S; Ometto, R; Vincenzi, M, 1990) |
| "Based on its electrophysiologic characteristics, encainide, a new type 1 antiarrhythmic agent, was selected for a therapeutic trial in a case of refractory paroxysmal atrial fibrillation." | 7.67 | The use of encainide in atrial fibrillation. ( Reid, PR; Vlay, SC, 1984) |
| "We determined the effects of single intravenous (10 mg) and oral (80, 160 mg) doses of verapamil in 8 digitalized patients with chronic atrial fibrillation." | 7.67 | Verapamil in chronic atrial fibrillation: variable patterns of response in ventricular rate. ( Carruthers, SG; Donner, AP; Gulamhusein, S; Klein, GJ; Twum-Barima, Y, 1984) |
| "It has earlier been shown that verapamil given intravenously or orally in sufficiently high single doses, may result in regular ventricular rhythm in patients with atrial fibrillation." | 7.67 | Long-term oral treatment with high doses of verapamil in lone atrial fibrillation. ( Johansson, PA; Olsson, SB, 1984) |
| "Of 18 patients who attended accident and emergency departments with pre-excited atrial fibrillation, 10 were inappropriately treated with intravenous verapamil." | 7.67 | Misuse of verapamil in pre-excited atrial fibrillation. ( Antoniou, A; Camm, AJ; Garratt, C; Ward, D, 1989) |
| " We report the case of a patient with WPW syndrome in whom inappropriate administration of verapamil during an episode of atrial fibrillation and rapid ventricular response caused ventricular fibrillation." | 7.67 | [Wolff-Parkinson-White syndrome and verapamil: apropos of a case of ventricular fibrillation]. ( Goy, JJ; Kappenberger, L; Michel, B, 1989) |
| "The efficacy of the association of verapamil plus quinidine in 70 patients with atrial fibrillation, 64 of them after having cardiac surgery, was assessed." | 7.67 | [Combination of quinidine and verapamil in auricular fibrillation]. ( Calvo, L; Maté, I; Mesa, JM; Moreno, I; Plaza, I; Rico, J; Sobrino, JA, 1989) |
| " We report a patient with atrial flutter-fibrillation who developed cyclic sinus node dysfunction with profound ventricular pauses in response to small doses of digoxin, verapamil, and propranolol, which resolved with discontinuation of the medications." | 7.67 | Hyperthyroid-induced atrial flutter-fibrillation with profound sinoatrial nodal pauses due to small doses of digoxin, verapamil, and propranolol. ( Hurst, JW; Talley, JD; Wathen, MS, 1989) |
| "Both verapamil and diltiazem are used to control ventricular response during atrial fibrillation (AF)." | 7.67 | Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation. ( Dubuc, M; Fromer, M; Kus, T; LeBlanc, RA; Nadeau, R; Shenasa, M, 1988) |
| "After the administration of verapamil for rapid tachycardias, five patients developed ventricular fibrillation or required urgent cardioversion." | 7.67 | Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome. ( Garan, H; McGovern, B; Ruskin, JN, 1986) |
| "A 29-year-old man with Wolff-Parkinson-White syndrome and atrial fibrillation developed fatal ventricular fibrillation shortly after receiving intravenous verapamil." | 7.67 | Fatal ventricular fibrillation following verapamil in Wolff-Parkinson-White syndrome with atrial fibrillation. ( Gianelly, RE; Jacob, AS; Nielsen, DH, 1985) |
| "The efficacy of verapamil and propranolol was studied in comparison with disopyramide on the atrial fibrillation experimentally induced in the dog heart in situ by electrical stimulation combined with intra-aortic injection of acetylcholine (ACh)." | 7.67 | Efficacy of disopyramide in comparison with verapamil and propranolol in the prevention of acetylcholine-induced atrial fibrillation in the dog. ( Bertrix, L; Bouzouita, K; Faucon, G; Lakhal, M; Lang, J; Timour Chah, Q, 1985) |
| "We reported recently that in patients suffering from atrial fibrillation and being refractory to antifibrillatory therapy with quinidine conversion to sinus rhythm can often be achieved by additional doses of verapamil." | 7.66 | [Enhancement of the antifibrillatory efficacy of quinidine in atrial fibrillation by verapamil (author's transl)]. ( Bender, F; Gülker, H; Heuer, H; Thale, J, 1982) |
| "Certain general conclusions suggest themselves on the basis of our extensive experience with treating arrhythmias in patients following open heart surgery, our specific results with verapamil therapy in the treatment of atrial fibrillation and atrial flutter in patients following open heart surgery, and the results of verapamil therapy administered in other groups of patients." | 7.66 | Verapamil therapy in the treatment of supraventricular arrhythmias following open heart surgery. ( Arciniegas, JG; Henthorn, RW; Plumb, VJ; Waldo, AL; Zimmern, SH, 1983) |
| "We examined the electrophysiologic effects of verapamil in eight patients with the Wolff-Parkinson-White syndrome." | 7.66 | Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. ( Carruthers, SG; Gulamhusein, S; Klein, GJ; Ko, P, 1982) |
| "20 patients with atrial fibrillation and rapid ventricular response were treated with the new calcium-antagonist Gallopamil." | 7.66 | [Heart rate reduction in atrial fibrillation with a rapid ventricular response by Gallopamil, a Ca-antagonist (author's transl)]. ( Buss, J; Horn, HG; Mitrović, V; Neuss, H; Schlepper, M, 1982) |
| "The pharmacokinetic parameters and oral bioavailability of the antiarrhythmic drug verapamil were determined in six patients with atrial fibrillation." | 7.66 | Clinical pharmacokinetics of verapamil in patients with atrial fibrillation. ( Anderson, P; BondessoN, U; Sylvén, C, 1982) |
| "The effects of intravenous verapamil on the electrophysiologic properties of the accessory pathway in 12 patients with symptomatic Wolff-Parkinson-White syndrome were studied using intracardiac electrical recordings." | 7.66 | Effects of verapamil on the electrophysiologic properties of the accessory pathway in patients with the Wolff-Parkinson-White syndrome. ( Anderson, S; Federman, J; Harper, RW; Middlebrook, K; Pitt, A; Whitford, E, 1982) |
| "The effects of physical exercise, isoproterenol and atropine upon the ventricular rate and regularity were studied in 12 patients with atrial fibrillation (AF) during verapamil-induced regular ventricular rhythm." | 7.66 | Verapamil-induced ventricular regularity in atrial fibrillation. Effects of exercise, isoproterenol, atropine and conversion to sinus rhythm. ( Khalsa, A; Olsson, SB, 1979) |
| "The acute effect of verapamil on the ventricular rate in atrial fibrillation and flutter was studied in 15 patients, 13 of whom had heart rate inadequately controlled with digitalis." | 7.66 | Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter. ( Dominic, J; Kuo, CS; McAllister, RG; Reddy, CP; Surawicz, B, 1979) |
| "The influence of practolol or verapamil on the activity of digoxin in atrial fibrillation has been studied in 16 hospitalized patients by determining plasma levels of the cardiac glycoside and its effects on the ventricular rate, before and during the association with each of the above drugs." | 7.65 | Plasma digoxin concentrations in patients with atrial fibrillation and indications for the association with other antiarrhythmic agents. ( Cargnelli, G; Domeneghetti, F; Ferrari, M; Malacini, P; Roberti, G, 1977) |
| "The haemodynamic effect of intravenous verapamil was assessed in eight digitalised patients with atrial fibrillation, at rest and on exercise." | 7.65 | Haemodynamic effect of intravenous verapamil in controlled atrial fibrillation. ( Ramshaw, J; Sloman, G; Spokes, J; Vohra, J, 1975) |
| "Verapamil was administered intravenously to 250 patients aged between 14 and 85, suffering from tachyarrhythmia of various type." | 7.65 | [Clinical results with verapamil in intravenous administration in the emergency therapy of cardiac arrhythmias]. ( Amoroso, A, 1975) |
| "The effects of intravenous verapamil on the electrocardiogram in 15 patients with heart disease in sinus rhythm and in 44 patients with supraventricular and ventricular tachyarrhythmias were evaluated." | 7.65 | Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. ( Heng, MK; Mercer, CJ; Norris, RM; Roche, AH; Singh, BN, 1975) |
| "Verapamil was administered by intravenous injection to 181 patients with various cardiac arrhythmias." | 7.65 | Immediate effects of intravenous verapamil in cardiac arrhythmias. ( Garrett, C; Krikler, DM; Schamroth, L, 1972) |
| " Abbreviated dosing of verapamil prior to cardioversion improves outcome at 1 week postcardioversion." | 6.72 | Signal-averaged P wave reflects change in atrial electrophysiological substrate afforded by verapamil following cardioversion from atrial fibrillation. ( Lane, J; Redfearn, DP; Skanes, AC; Stafford, PJ, 2006) |
| "Amiodarone and verapamil have been employed to treat immediate recurrences of AF (IRAF) after cardioversion." | 6.71 | Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion. ( Behrens, S; Kamke, W; Stahn, A; Sticherling, C; Zabel, M, 2005) |
| " If sinus rhythm could not be established at that time, electric cardioversion was performed and the drug was continued in lower dosage thereafter." | 6.67 | [Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation--conversion and 12-month follow-up--a randomized comparison]. ( Betz, P; Kalusche, D; Roskamm, H; Stockinger, J, 1994) |
| "Propafenone is a class 1c antiarrhythmic agent that has an electrophysiologic profile suggesting that it might be potentially effective in recent-onset AF." | 6.67 | Clinical course of recent-onset atrial fibrillation treated with oral propafenone. ( Ganam, R; Ganem, R; Rabner, M; Weiner, P; Zidan, F, 1994) |
| "Verapamil caused a lower ventricular rate, but only six (19%) of the patients (n = 31) converted to sinus rhythm within 4 h (p < 0." | 6.67 | The effect of magnesium versus verapamil on supraventricular arrhythmias. ( Birkeland, K; Gullestad, L; Høyer, MM; Kjekshus, J; Mølstad, P; Vanberg, P, 1993) |
| "Treatment with atenolol was associated with a marked reduction in maximum treadmill walking distance (mean 356 m) as compared both with placebo (mean 421 m, p less than 0." | 6.66 | Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. ( Lewis, RV; McDevitt, DG; McMurray, J, 1989) |
| "When verapamil treatment was stopped, the patient experienced AF recurrence." | 5.51 | Treatment with verapamil for restoration of sinus rhythm in atrial fibrillation with rapid ventricular response: A case report. ( Chen, L; Liang, D; Lin, J; Lin, Y; Qi, G; Tian, W; Wang, X, 2019) |
| "Verapamil treatment resulted in a significant decrease in the longest pacing CL at which DA was induced (207+/-19 vs 178+/-17 ms, p<0." | 5.33 | Discordant repolarization alternans-induced atrial fibrillation is suppressed by verapamil. ( Furukawa, Y; Hiromoto, K; Kanemori, T; Masuyama, T; Mine, T; Ohyanagi, M; Shimizu, H, 2005) |
| "Verapamil was administered at a loading dose of 0." | 5.31 | Profibrillatory effects of verapamil but not of digoxin in the goat model of atrial fibrillation. ( Allessie, MA; Duytschaever, MF; Garratt, CJ, 2000) |
| "Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem." | 5.31 | Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs. ( Bénardeau, A; Fareh, S; Nattel, S, 2001) |
| "The emergency physician diagnosed a cardiac arrest." | 5.30 | [Torsade de pointes tachycardia during administration of quinidine and verapamil in atrial fibrillation]. ( Karch, M; Plewan, A; Schmidt, G; Schmitt, C; Schömig, A, 1997) |
| "Verapamil may cause detrimental results when given to patients with the Wolff-Parkinson-White syndrome and atrial fibrillation." | 5.28 | Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation. ( Agmon, J; Katz, A; Ovsyscher, IA; Rechavia, E; Sagie, A; Sclarovsky, S; Strasberg, B, 1989) |
| " Trough serum concentration of verapamil did not differ during the two dosage regimens (59 ng/ml - conventional formulation and 49." | 5.27 | 24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation. ( Bjerregaard, P; Jørgensen, HS; Klitgaard, NA; Mølgaard, H, 1987) |
| "Verapamil disposition was studied in 12 patients with chronic and fibrillation." | 5.26 | Verapamil disposition kinetics in chronic atrial fibrillation. ( Harapat, S; Harrison, DC; Kates, RE; Keefe, DL; Kirsten, EB; Schwartz, J, 1981) |
| "Verapamil is a novel antiarrhythmic agent which appears to act as a calcium-ion antagonist, blocking calcium transport across the myocardial cell membrane." | 5.25 | [Verapamil in the study and treatment of supraventricular tachycardias, with special reference to pre-excitation]. ( Krikler, DM, 1975) |
| "The VERDICT (Verapamil Versus Digoxin and Acute Versus Routine Serial Cardioversion Trial) is a prospective, randomized study to investigate whether: 1) acutely repeated serial electrical cardioversions (ECVs) after a relapse of atrial fibrillation (AF); and 2) prevention of intracellular calcium overload by verapamil, decrease intractability of AF." | 5.12 | Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. ( Bosker, HA; Crijns, HJ; Hemels, ME; Ranchor, AV; Van den Berg, MP; Van Gelder, IC; Van Noord, T; Van Veldhuisen, DJ; Veeger, NJ; Wiesfeld, AC, 2006) |
| "100 consecutive patients with atrial fibrillation (AF) of at least four weeks' duration and indications for cardioversion were assigned randomly to two groups, one treated with verapamil (verapamil group) and the other with digoxin (digoxin group) before cardioversion." | 5.11 | Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil. ( Edvardsson, N; Firsovaite, V; Fredholm, O; Kronvall, T; Lindholm, CJ; Meurling, CJ; Möller, SJ; Olsson, SB; Pettersson, T; Platonov, PG; Roijer, A, 2004) |
| "While verapamil has been proposed as a treatment for reducing electrophysiological remodeling due to atrial fibrillation and atrial tachyarrhythmias, no previous study has tested its effects in brady-tachy patients implanted with a dual-chamber pacemaker." | 5.11 | A controlled study on the effect of verapamil on atrial tachycaarrhythmias in patients with brady-tachy syndrome implanted with a DDDR pacemaker. ( Bertaglia, E; Biffi, M; Boriani, G; Branzi, A; Carboni, A; Latini, R; Martignani, C; Sciotto, F, 2005) |
| "Verapamil and ibutilide blunt the atrial fibrillation-induced shortening of atrial refractoriness that may predispose to an immediate recurrence of atrial fibrillation after cardioversion." | 5.10 | Comparison of verapamil and ibutilide for the suppression of immediate recurrences of atrial fibrillation after transthoracic cardioversion. ( Knight, BP; Morady, F; Oral, H; Ozaydin, M; Pelosi, F; Sticherling, C; Strickberger, SA; Tada, H, 2002) |
| "The aim of this prospective, randomized study was to investigate the effect of pretreatment with two different intracellular calcium-lowering drugs (verapamil and metoprolol) on recovery from atrial effective refractory period (AERP) shortening after internal electrical cardioversion (EC) of persistent atrial fibrillation (AF) in patients on amiodarone." | 5.10 | Effects of verapamil and metoprolol on recovery from atrial electrical remodeling after cardioversion of long-lasting atrial fibrillation. ( Bertaglia, E; D'Este, D; Michieletto, M; Pascotto, P; Zerbo, F, 2003) |
| "To evaluate the impact, on atrial fibrillation (AF) recurrences, of verapamil addition to a class IC or III antiarrhythmic drug in patients, with persistent AF, who underwent an electrical cardioversion (EC)." | 5.10 | VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). ( Alfano, F; Campana, A; Canciello, M; De Fabrizio, G; De Matteis, C; De Pasquale, M; De Simone, A; Di Mauro, M; Manzo, M; Sabino, L; Stabile, G; Turco, P; Vitale, DF, 2003) |
| "To evaluate, in a prospective and randomized fashion, the efficacy of a pretreatment with verapamil (V) in reducing recurrences of atrial fibrillation (AF) after electrical cardioversion (C)." | 5.09 | Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. ( De Matteis, C; De Simone, A; Di Napoli, T; Di Stasio, M; Gasparini, M; Petrazzuoli, F; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 1999) |
| "We studied the effects of the mode of cardioversion on Doppler left atrial and appendage function in 19 patients with persistent atrial fibrillation (> or = 4 weeks), who were randomized to pharmacological (quinidine) or electrical cardioversion (protocol: 200, 300, 360 J) after pre-treatment with verapamil." | 5.09 | Left atrial and appendage mechanical function after pharmacological or electrical cardioversion in patients with chronic atrial fibrillation: a multicenter, randomized study. ( Cattarini, G; Mazzone, C; Miccio, M; Morgera, T; Pandullo, C; Salvi, R; Scardi, S, 2000) |
| "The purpose of this study was to assess the effect of verapamil on immediate recurrences of atrial fibrillation occurring after successful electrical cardioversion." | 5.09 | Effect of verapamil on immediate recurrence of atrial fibrillation. ( Augostini, R; Daoud, EG; Hummel, JD; Kalbfleisch, SJ; Williams, S, 2000) |
| "Racemic (R /S)- verapamil is widely used in the management of chronic atrial fibrillation." | 5.09 | Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. ( Busse, D; Drescher, S; Eichelbaum, M; Fromm, MF; Kühlkamp, V; Mörike, K, 2001) |
| "The role of verapamil in the prevention of atrial fibrillation (AF) in patients with recurrent AF is unknown." | 5.09 | Effect of verapamil on prevention of atrial fibrillation in patients implanted with an implantable atrial defibrillator. ( Ayers, GM; Lau, CP; Tse, HF; Wang, Q; Yu, CM, 2001) |
| "The role of digoxin and verapamil in the control of ventricular response in rapid atrial fibrillation is well established." | 5.09 | Clinical assessment of clonidine in the treatment of new-onset rapid atrial fibrillation: a prospective, randomized clinical trial. ( Abdollah, H; Ghali, WA; Moritz, S; Sanfilippo, AJ; Simpson, CS, 2001) |
| "Atrial fibrillation occurred in 15% of the patients receiving placebo and in 8% of the patients receiving verapamil (difference not significant)." | 5.08 | Verapamil as prophylactic treatment for atrial fibrillation after lung operations. ( Demedts, M; Demuynck, K; Deneffe, G; Lacquet, L; Tits, G; Tjandra-Maga, T; Van Mieghem, W, 1996) |
| "To determine the relative effectiveness of a verapamil-quinidine sequential combination versus digoxin-quinidine in the emergency department treatment of paroxysmal atrial fibrillation (PAF)." | 5.08 | Effectiveness of verapamil-quinidine versus digoxin-quinidine in the emergency department treatment of paroxysmal atrial fibrillation. ( Dillon, EC; Innes, GD; Metcalfe, C; Vertesi, L, 1997) |
| "An evaluation of amiodarone as prophylactic treatment for supraventricular tachyarrhythmias after pulmonary surgery was stopped because of a high incidence of the adult respiratory distress syndrome (ARDS) after a pneumonectomy." | 5.07 | Amiodarone and the development of ARDS after lung surgery. ( Coolen, L; Demedts, MG; Deneffe, GJ; Lacquet, LM; Malysse, I; Van Mieghem, W, 1994) |
| "In a placebo-controlled study the effects on ventricular rate regulation and exercise performance of xamoterol, 100 mg two times a day and 200 mg two times a day, and slow-release verapamil, 240 mg once a day, were assessed in 21 patients with chronic atrial fibrillation." | 5.07 | Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation. ( Lundström, T; Moor, E; Rydén, L, 1992) |
| "Efficacy and safety of intravenous flecainide (2 mg/kg body weight in 10 minutes), verapamil (10 mg in 1 minute), and propafenone (2 mg/kg body weight in 10 minutes) were investigated in 90 consecutive patients with atrial fibrillation (AF) or flutter (AFL)." | 5.07 | Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. ( Kingma, JH; Suttorp, MJ, 1992) |
| "In 69 consecutive patients with recent-onset atrial fibrillation, we compared the usefulness of verapamil, flecainide and propafenone for the acute conversion to sinus rhythm within 1 hour of the start of intravenous infusion." | 5.06 | Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm. ( Kastrati, A; Kondili, A; Popa, Y, 1990) |
| "In an open clinical trial, the therapeutic effect of sustained-release verapamil hydrochloride was investigated in 40 patients with chronic atrial fibrillation." | 5.06 | [Delayed-release verapamil hydrochloride in chronic atrial fibrillation. Reducing the heart rate]. ( Gonska, BD; Wiedey, KD, 1990) |
| "The effects of two calcium channel blockers, diltiazem (270 mg/day) and verapamil (240 mg/day), were studied in 18 patients with chronic atrial fibrillation." | 5.06 | Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. ( Lundström, T; Rydén, L, 1990) |
| "In a single-blind randomized study, the efficacy of intravenous flecainide (2 mg/kg/10 minutes) versus verapamil (10 mg/1 minute) was assessed in 40 patients with paroxysmal atrial fibrillation (AF) or atrial flutter (AFI)." | 5.06 | Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. ( Kingma, JH; Lie-A-Huen, L; Mast, EG; Suttorp, MJ, 1989) |
| "The effects of esmolol, an ultrashort-acting beta blocker, and verapamil were compared in controlling ventricular response in 45 patients with atrial fibrillation or atrial flutter, in a randomized, parallel, open-label study." | 5.06 | Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. ( Das, G; Michelson, EL; Platia, EV; Porterfield, JK, 1989) |
| "This study has compared the effect on heart rate control of the addition of pindolol 15 mg bd or verapamil 40 mg tds to maintenance digoxin therapy in 12 patients with chronic atrial fibrillation." | 5.06 | Improved control of atrial fibrillation with combined pindolol and digoxin therapy. ( Channer, KS; James, MA; Papouchado, M; Rees, JR, 1989) |
| "It has been suggested that patients in whom atrial fibrillation (AF) is associated with poor exercise tolerance respond better to treatment with xamoterol plus digoxin than to digoxin alone; this may be attributable to better control of exercise induced tachycardia." | 5.06 | Factors affecting the clinical response to treatment with digoxin and two calcium antagonists in patients with atrial fibrillation. ( Lewis, RV; McDevitt, DG, 1988) |
| "Six patients with chronic atrial fibrillation (AF) took single doses of digoxin, verapamil and diltiazem, alone and in combination." | 5.06 | Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. ( Irvine, N; Lewis, RV; McDevitt, DG, 1988) |
| " The efficacy of verapamil alone, or in combination with digoxin, was compared with digoxin alone in eight patients with chronic atrial fibrillation in this double-blind placebo-controlled study." | 5.06 | Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation. ( Beasley, CR; Challenor, V; Holgate, ST; Pomfret, SM, 1988) |
| "Patients with atrial fibrillation frequently show a wide variation in heart rate with digoxin therapy." | 5.06 | Towards improved control of atrial fibrillation. ( Channer, KS; James, MA; Papouchado, M; Pitcher, DW; Rees, JR, 1987) |
| "Twelve patients (including 2 females) with chronic atrial fibrillation were entered into a randomized, double blind crossover study to compare the effects of digoxin and verapamil upon heart rate, exercise tolerance and symptom control." | 5.06 | A comparison of verapamil and digoxin in the treatment of atrial fibrillation. ( Lakhani, M; Lewis, R; McDevitt, DG; Moreland, TA, 1987) |
| "The efficacy and safety of oral verapamil, 240 mg, with or without digoxin were studied in 52 patients with chronic atrial fibrillation at rest, and during mild and maximal exercise." | 5.05 | Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. ( David, D; Di Segni, E; Guerrero, J; Kaplinsky, E; Klein, HO; Lang, R; Levy, A; Sareli, P; Weiss, E, 1983) |
| "The safety and efficacy of oral verapamil to control exercise tachycardia in 27 patients with atrial fibrillation and 3 with atrial flutter receiving digitalis was evaluated in a double-blind, randomized, crossover study." | 5.05 | Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis. ( Baessler, C; Morganroth, J; Panidis, IP, 1983) |
| "Hemodynamic effects of the beta-receptor-blocking agent metoprolol (100 mg orally) and the calcium antagonist verapamil (160 mg orally) were analyzed in 24 patients with atrial fibrillation of different etiology (idiopathic atrial fibrillation, 6 cases; congestive cardiomyopathy, 6 cases; mitral stenosis, 5 cases; mitral regurgitation, 6 cases)." | 5.05 | [Modification of hemodynamics in tachycardiac atrial fibrillation by metoprolol and verapamil]. ( Bilgin, Y; Gigler, G; Maier, WD; Neuss, H; Schlepper, M; Thormann, J, 1983) |
| "The safety and efficacy of the intravenous (IV) calcium channel blocker, verapamil, in controlling the ventricular response or converting to sinus rhythm patients with atrial flutter or atrial fibrillation were assessed." | 5.05 | Atrial fibrillation and flutter. Immediate control and conversion with intravenously administered verapamil. ( McDonough, T; Parker, M; Talano, JV; Tommaso, C, 1983) |
| "Fourteen patients with onset of atrial fibrillation (11) or flutter (three) and ventricular rate over 120 beats per minute following cardiac surgery were treated with intravenous (IV) doses of verapamil hydrochloride or placebo in a double-blind crossover protocol." | 5.05 | Double-blind crossover randomized trial of intravenously administered verapamil. Its use for atrial fibrillation and flutter following open heart surgery. ( Danoviz, J; Gunnar, RM; Hwang, MH; Loeb, HS; Pacold, I; Rad, N, 1984) |
| "Oral verapamil has previously been shown to reduce heart rate at rest and during mild exercise in chronic atrial fibrillation." | 5.05 | Verapamil improves exercise capacity in chronic atrial fibrillation: double-blind crossover study. ( David, D; Di Segni, E; Gefen, J; Guerrero, J; Kaplinsky, E; Klein, HO; Lang, R; Libhaber, C; Sareli, P; Weiss, E, 1983) |
| "Verapamil or placebo was administered as a bolus infusion in a double-blind fashion to 24 patients with either atrial fibrillation or flutter and to ten patients with paroxysmal supraventricular tachycardia." | 5.05 | Treatment of supraventricular arrhythmias with intravenous and oral verapamil. ( Gonzalez, R; Scheinman, MM, 1981) |
| "We evaluated the effectiveness of oral verapamil therapy for control of ventricular rate in digitalized patients with atrial fibrillation (AF) with three clinical problems: chronic AF with rapid rate at rest (four patients), chronic AF with accelerated rate during modest exercise (five patients), and rapid rates during paroxysmal AF (four patients)." | 5.05 | Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation. ( Guerrero, J; King, BD; Pitchon, R; Schneider, RR; Stern, EH; Wiener, I, 1982) |
| "The effectiveness of verapamil in controlling ventricular rate was evaluated in 20 patients with atrial fibrillation or flutter with a rapid ventricular response (Group 1) and 30 patients with paroxysmal supraventricular tachycardia (Group 2)." | 5.05 | Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study. ( Appel, R; Myerburg, RJ; Sung, RJ; Waxman, HL, 1981) |
| "The comparative effects of diltiazem and verapamil in 30 patients with long-standing atrial fibrillation were evaluated in a prospective clinical trial." | 5.05 | Diltiazem, verapamil, and quinidine in patients with chronic atrial fibrillation. ( Anda, L; Eichelbaum, M; Greenblatt, DJ; Ochs, HR, 1985) |
| "A double-blind randomized study was performed to compare the efficacy of intravenous verapamil with saline in 28 patients with a rapid ventricular rate and atrial fibrillation or atrial flutter." | 5.04 | Verapamil in atrial fibrillation and atrial flutter. ( Aronow, WS; Ferlinz, J; Karlsberg, RP; Landa, D; Plasencia, G; Wong, R, 1979) |
| "The calcium-channel blockers verapamil or diltiazem, or select beta-blockers are efficacious for heart rate control at rest and during exercise for patients with atrial fibrillation without a clinically important decrease in exercise tolerance." | 4.80 | The evidence regarding the drugs used for ventricular rate control. ( Bass, EB; Goodman, SN; Kim, N; McNamara, RL; Miller, MR; Powe, NR; Robinson, K; Segal, JB; Yu, D, 2000) |
| " A 59-year-old woman had a permanent pacemaker implanted after diagnosis of tachycardia-bradycardia syndrome, and her drug regimen of digoxin, verapamil, and warfarin was supplemented with flecainide to prevent paroxysmal atrial fibrillation." | 4.78 | Interference by antiarrhythmic agents with function of electrical cardiac devices. ( Bauman, JL; Ezri, M; Nazari, J; Tworek, DA, 1992) |
| " Verapamil is extremely effective in patients with supraventricular tachyarrhythmias, hypertrophic cardiomyopathy, and the various anginal syndromes, but it appears to be ineffective or possibly even deleterious in those with pulmonary hypertension, congestive heart failure of any cause, and Raynaud's phenomenon or disease." | 4.77 | Calcium antagonists in patients with cardiovascular disease. Current perspectives. ( Hillis, LD; Winniford, MD, 1985) |
| " Verapamil remains the most widely used calcium antagonist for the treatment of cardiac arrhythmias." | 4.76 | Verapamil in cardiac arrhythmias: an overview. ( Vohra, J, 1982) |
| "It is clear from clinical and experimental data that have been reported thus far that verapamil is highly effective in the therapy of cardiac arrhythmias, and that it acts by a different mechanism than most of the commonly used antiarrhythmic drugs." | 4.75 | Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil. ( Hoffman, BF; Rosen, MR; Wit, AL, 1975) |
| "In the JADER analysis, hemorrhage was significantly associated with treatment with edoxaban and verapamil (reporting odds ratio = 1." | 4.31 | Association between hemorrhage and direct oral anticoagulants in combination with verapamil: Analysis of Japanese Adverse Drug Event Report database and electronic medical record data. ( Hosomi, K; Komatsu, Y; Takegami, M; Yodoshi, M; Yokoyama, S, 2023) |
| " The purpose of the article is to evaluate the incidence of UTI in patients with supraventricular arrhythmia after arrhythmia relief with verapamil." | 4.12 | Comments of the editorial board on the article "The incidence of atrial infarction in patients with supraventricular arrhythmias" (authors: Bocharov A.V., Popov L.V. DOI:10.18087/cardio.2022.3.n1648). ( Editorial, A, 2022) |
| " We herein report an elderly patient with CKD who suffered bradycardia shock after the combined use of carteolol eye drops and verapamil for glaucoma and paroxysmal AF." | 4.02 | Bradycardia Shock Caused by the Combined Use of Carteolol Eye Drops and Verapamil in an Elderly Patient with Atrial Fibrillation and Chronic Kidney Disease. ( Akutsu, N; Arai, R; Fukamachi, D; Monden, M; Murata, N; Okumura, Y, 2021) |
| " Verapamil hydrochloride and diltiazem hydrochloride are combined P-glycoprotein (P-gp) and CYP3A4 inhibitors and may be associated with increases in the risk of bleeding with DOACs." | 3.96 | Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function. ( Brown, JD; Lesko, L; Lip, GYH; Pham, P; Schmidt, S, 2020) |
| "Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients." | 3.96 | Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. ( Bahteeva, D; Bochkov, P; Cherniaeva, M; Golovina, O; Gorbatenkova, S; Kulikova, M; Mirzaev, K; Ostroumova, O; Rytkin, E; Shevchenko, R; Sychev, D, 2020) |
| "Rivaroxaban is indicated for stroke prevention in nonvalvular atrial fibrillation (AF)." | 3.91 | Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban. ( Chan, ECY; Cheong, EJY; Chua, DXY; Teo, DWX, 2019) |
| "Two groups of subjects, with rapid atrial fibrillation, received intravenous Digoxin (n = 9) or verapamil (n = 8), for heart rate control." | 3.88 | Hypermagnesuria in Humans Following Acute Intravenous Administration of Digoxin. ( Abu-Amer, N; Farfel, Z; Karlish, SJD; Mayan, H; Priel, E, 2018) |
| "Simvastatin (SV) leads to reduction of ventricular rhythm during atrial fibrillation on rabbit atrioventricular (AV) nodes." | 3.81 | Acute effects of simvastatin to terminate fast reentrant tachycardia through increasing wavelength of atrioventricular nodal reentrant tachycardia circuit. ( Alizadeh, AM; Aminolsharieh Najafi, S; Khori, V; Moheimani, HR; Nayebpour, M; Shakiba, D; Zahedi, M, 2015) |
| "There is evidence that verapamil promotes the persistence of paroxysmal atrial fibrillation (AF)." | 3.76 | Verapamil eliminates the hierarchical nature of activation frequencies from the pulmonary veins to the atria during paroxysmal atrial fibrillation. ( Hasebe, H; Kamiya, K; Kodama, I; Kuroda, Y; Kushiyama, Y; Osaka, T; Yokoyama, E, 2010) |
| " The pharmacokinetics of verapamil and of one of its metabolites, norverapamil, is changed after multiple oral dosing as has been described in patients with supraventricular tachyarrhythmias, angina pectoris or in patients with essential hypertension." | 3.76 | Pharmacokinetics of calcium channel blocking agents. ( Anderson, P, 1986) |
| " To study the possible role of EAD in spontaneous initiation of atrial fibrillation (AF), we tested the effects of L-type Ca(2+) channel blocker verapamil in canine models of cholinergic-dependent AF." | 3.72 | [Effects of verapamil on atrial fibrillation spontaneous initiation in the intact canine heart]. ( Beloshapko, GG; Fedorov, VV; Glukhov, AV; Iushmanova, AV; Rozenshtraukh, LV; Sharifov, OF, 2003) |
| "To assess effect of calcium antagonists amlodipine and verapamil on the risk of development of atrial fibrillation after coronary artery bypass surgery." | 3.72 | [Effect of calcium antagonists verapamil and amlodipine on the risk of development of atrial fibrillation after coronary artery bypass grafting]. ( Afanas'ev, SA; Akhmedov, ShD; Antonchenko, IV; Dzhavadova, GK; Evtushenko, AV; Kandinskiĭ, ML; Kozlov, BN; Popov, SV; Shipulin, VM; Vecherskiĭ, IuIu, 2003) |
| "5-Fluorouracil, a widely used drug in cancer treatment, is known to have cardiotoxic effects: chest pain with ECG changes, arrhythmias, arterial hypertension or hypotension, myocardial infarction, cardiogenic shock and sudden death have been described in the literature." | 3.72 | Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases. ( Alberti, A; Corrada, E; Ferrari, S; Mafrici, A; Marenna, B, 2003) |
| "To analyze action of digoxin and some non-digitalis drugs (beta-blockers, verapamil, amiodarone, d,l-sotalol) and their combinations on electrical activity of atria, frequency and structure of ventricular rhythm in patients with permanent atrial fibrillation." | 3.72 | [Correction of rate and structure of ventricular rhythm in permanent atrial fibrillation: a novel pathogenetic approach]. ( Blagova, OV; Bogdanova, EA; Nedostup, AV; Platonova, AA, 2004) |
| "The purpose of this study was to evaluate the effects of an acute increase in atrial pressure on refractoriness (mechanoelectrical feedback) and the vulnerability to atrial fibrillation (AF) and to investigate the effects of autonomic blockade and verapamil on mechanoelectrical feedback in humans." | 3.71 | Effects of simultaneous atrioventricular pacing on atrial refractoriness and atrial fibrillation inducibility: role of atrial mechanoelectrical feedback. ( Knight, BP; Morady, F; Oral, H; Pelosi, F; Strickberger, SA; Tse, HF, 2001) |
| "The objective was to assess the effect ofverapamil on atrial fibrillation (AF) cycle length and spatial dispersion of refractoriness in patients with chronic AF." | 3.71 | Increased dispersion and shortened refractoriness caused by verapamil in chronic atrial fibrillation. ( de Bakker, JM; Elvan, A; Hauer, RN; Ramanna, H; Robles de Medina, EO; Wittkampf, FH, 2001) |
| "We present a case report describing an interaction between topical timolol maleate, verapamil, and flecainide resulting in symptomatic bradycardia." | 3.71 | Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report. ( Herd, A; Minish, T, 2002) |
| "Verapamil is an effective drug to slow ventricular rate in atrial fibrillation (AF)." | 3.70 | Verapamil prolongs atrial fibrillation by evoking an intense sympathetic neurohumoral effect. ( Dai, CP; Friedman, HS; Hussain, A; Mallipeddi, D; Rodney, E; Sharafkhaneh, A; Sinha, A; Sinha, B; Wattanasuwan, N; Win, M, 1999) |
| "The aim of our study was to verify the effect of oral administration of verapamil on atrial electrophysiologic characteristics after cardioversion of persistent atrial fibrillation (AF) in humans." | 3.70 | Postcardioversion atrial electrophysiologic changes induced by oral verapamil in patients with persistent atrial fibrillation. ( Bianconi, L; Calò, L; Castro, A; Gentilucci, G; Lamberti, F; Pandozi, C; Santini, M; Scianaro, MC, 2000) |
| "Electrical remodelling with shortening of the atrial refractory period and increased fibrillatory rate occurs after onset of atrial fibrillation and can be attenuated by pre-treatment with intravenous verapamil." | 3.70 | Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil. ( Carlson, J; Ingemansson, MP; Lindholm, CJ; Meurling, CJ; Olsson, SB; Roijer, A; Smideberg, B; Sornmo, L; Stridh, M, 1999) |
| "To review the safety and efficacy of verapamil and diltiazem with respect to ventricular response in atrial fibrillation (AF) in the setting of left ventricular (LV) systolic dysfunction." | 3.69 | Calcium channel blockers for heart rate control in atrial fibrillation complicated by congestive heart failure. ( Heywood, JT, 1995) |
| "The antiarrhythmic properties of sublingual verapamil were investigated in seven patients with acute fast atrial flutter (n = 2) or fibrillation (n = 5)." | 3.69 | Preliminary investigation of the efficacy of sublingual verapamil in the management of acute atrial fibrillation and flutter. ( Fort, S; John, DN; Lewis, MJ; Luscombe, DK, 1994) |
| "Atrial contractile dysfunction after short-term atrial fibrillation is reduced by the calcium antagonist verapamil, which suggests that transsarcolemmal calcium influx contributed to this dysfunction." | 3.69 | Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. ( Aksnes, G; Christensen, G; Leistad, E; Verburg, E, 1996) |
| "We studied retrospectively 102 patients, 76 males, 26 females, mean age 56 +/- 12 years, with paroxysmal or sustained atrial fibrillation or atrial flutter (AFlut) treated with verapamil/quinidine (Cordichin) (dosage 3 to 5 times 1 tablet/day)." | 3.69 | [Conversion rate and prevention of recurrence of paroxysmal and sustained atrial fibrillation or atrial flutter with verapamil/quinidine]. ( Pfitzner, P; Trappe, HJ, 1996) |
| "Verapamil is used to control ventricular response during atrial fibrillation (AF)." | 3.68 | Effects of verapamil on electrophysiological properties in paroxysmal atrial fibrillation. ( Arakawa, K; Hamasaki, N; Kumagai, K; Matsuo, K; Moroe, K; Ono, M; Yamanouchi, Y, 1993) |
| "The aim was to evaluate the effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation." | 3.68 | Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. ( Haraguchi, M; Kusukawa, R; Matsuda, M; Matsuda, Y; Tada, T; Takahashi, T; Yamagishi, T, 1991) |
| "The Authors report a case of incessant torsade de pointes, associated with QT prolongation, due to the proarrhythmic effect of quinidine, which was successfully treated with i." | 3.68 | [Torsade de pointes induced by quinidine: a case treated successfully with verapamil]. ( Arfiero, S; Ometto, R; Vincenzi, M, 1990) |
| "Nineteen consecutive patients with atrial fibrillation/flutter or other types of supraventricular tachycardia were given intravenous (IV) calcium salts (1 g) followed by verapamil infusion at a rate of 1 mg/min." | 3.68 | Short-term control of supraventricular tachycardia with verapamil infusion and calcium pretreatment. ( Barnett, JC; Touchon, RC, 1990) |
| "Based on its electrophysiologic characteristics, encainide, a new type 1 antiarrhythmic agent, was selected for a therapeutic trial in a case of refractory paroxysmal atrial fibrillation." | 3.67 | The use of encainide in atrial fibrillation. ( Reid, PR; Vlay, SC, 1984) |
| "We determined the effects of single intravenous (10 mg) and oral (80, 160 mg) doses of verapamil in 8 digitalized patients with chronic atrial fibrillation." | 3.67 | Verapamil in chronic atrial fibrillation: variable patterns of response in ventricular rate. ( Carruthers, SG; Donner, AP; Gulamhusein, S; Klein, GJ; Twum-Barima, Y, 1984) |
| "Sudden death was recorded by continuous ambulatory electrocardiographic (Holter) monitoring in a 62 year old man with hypertrophic cardiomyopathy and atrial fibrillation, who had been treated for four days with verapamil 360 mg orally." | 3.67 | Verapamil: a cause of sudden death in a patient with hypertrophic cardiomyopathy. ( Danchin, N; Perrot, B; Terrier de la Chaise, A, 1984) |
| "It has earlier been shown that verapamil given intravenously or orally in sufficiently high single doses, may result in regular ventricular rhythm in patients with atrial fibrillation." | 3.67 | Long-term oral treatment with high doses of verapamil in lone atrial fibrillation. ( Johansson, PA; Olsson, SB, 1984) |
| "In 13 patients with chronic atrial fibrillation, programmed right ventricular pacing was performed before and after intravenous administration of 4 mg gallopamil." | 3.67 | [Regularization of ventricular intervals in atrial fibrillation--electrophysiologic findings on the underlying mechanism]. ( Golling, FR; Kindler, M; Neuss, H; Schlepper, M; Thormann, J; Weissmüller, P, 1984) |
| "Of 18 patients who attended accident and emergency departments with pre-excited atrial fibrillation, 10 were inappropriately treated with intravenous verapamil." | 3.67 | Misuse of verapamil in pre-excited atrial fibrillation. ( Antoniou, A; Camm, AJ; Garratt, C; Ward, D, 1989) |
| "A 61-year-old woman who was being treated with verapamil because of atrial fibrillation with rapid ventricular rate, went into anaphylactic shock." | 3.67 | [Anaphylactic shock after i.v. verapamil]. ( Fridensohn, A; Habot, B; Rabinowitz, H; Schlesinger, Z, 1989) |
| " We report the case of a patient with WPW syndrome in whom inappropriate administration of verapamil during an episode of atrial fibrillation and rapid ventricular response caused ventricular fibrillation." | 3.67 | [Wolff-Parkinson-White syndrome and verapamil: apropos of a case of ventricular fibrillation]. ( Goy, JJ; Kappenberger, L; Michel, B, 1989) |
| "The efficacy of the association of verapamil plus quinidine in 70 patients with atrial fibrillation, 64 of them after having cardiac surgery, was assessed." | 3.67 | [Combination of quinidine and verapamil in auricular fibrillation]. ( Calvo, L; Maté, I; Mesa, JM; Moreno, I; Plaza, I; Rico, J; Sobrino, JA, 1989) |
| " We report a patient with atrial flutter-fibrillation who developed cyclic sinus node dysfunction with profound ventricular pauses in response to small doses of digoxin, verapamil, and propranolol, which resolved with discontinuation of the medications." | 3.67 | Hyperthyroid-induced atrial flutter-fibrillation with profound sinoatrial nodal pauses due to small doses of digoxin, verapamil, and propranolol. ( Hurst, JW; Talley, JD; Wathen, MS, 1989) |
| "Both verapamil and diltiazem are used to control ventricular response during atrial fibrillation (AF)." | 3.67 | Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation. ( Dubuc, M; Fromer, M; Kus, T; LeBlanc, RA; Nadeau, R; Shenasa, M, 1988) |
| "After the administration of verapamil for rapid tachycardias, five patients developed ventricular fibrillation or required urgent cardioversion." | 3.67 | Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome. ( Garan, H; McGovern, B; Ruskin, JN, 1986) |
| "Intravenous verapamil hydrochloride was used alone in 63 episodes of atrial fibrillation and flutter and six episodes of supraventricular tachycardia (SVT) (group A)." | 3.67 | Treatment of atrial arrhythmias. Effectiveness of verapamil when preceded by calcium infusion. ( Habbab, MA; Haft, JI, 1986) |
| "A 29-year-old man with Wolff-Parkinson-White syndrome and atrial fibrillation developed fatal ventricular fibrillation shortly after receiving intravenous verapamil." | 3.67 | Fatal ventricular fibrillation following verapamil in Wolff-Parkinson-White syndrome with atrial fibrillation. ( Gianelly, RE; Jacob, AS; Nielsen, DH, 1985) |
| "The efficacy of verapamil and propranolol was studied in comparison with disopyramide on the atrial fibrillation experimentally induced in the dog heart in situ by electrical stimulation combined with intra-aortic injection of acetylcholine (ACh)." | 3.67 | Efficacy of disopyramide in comparison with verapamil and propranolol in the prevention of acetylcholine-induced atrial fibrillation in the dog. ( Bertrix, L; Bouzouita, K; Faucon, G; Lakhal, M; Lang, J; Timour Chah, Q, 1985) |
| "We reported recently that in patients suffering from atrial fibrillation and being refractory to antifibrillatory therapy with quinidine conversion to sinus rhythm can often be achieved by additional doses of verapamil." | 3.66 | [Enhancement of the antifibrillatory efficacy of quinidine in atrial fibrillation by verapamil (author's transl)]. ( Bender, F; Gülker, H; Heuer, H; Thale, J, 1982) |
| "Certain general conclusions suggest themselves on the basis of our extensive experience with treating arrhythmias in patients following open heart surgery, our specific results with verapamil therapy in the treatment of atrial fibrillation and atrial flutter in patients following open heart surgery, and the results of verapamil therapy administered in other groups of patients." | 3.66 | Verapamil therapy in the treatment of supraventricular arrhythmias following open heart surgery. ( Arciniegas, JG; Henthorn, RW; Plumb, VJ; Waldo, AL; Zimmern, SH, 1983) |
| "Forty-nine consecutive patients (44 with atrial fibrillation and five with atrial flutter) received 10 mg of verapamil five to seven minutes before elective electroversion, to evaluate the feasibility of the latter while verapamil effects were present." | 3.66 | Electroversion after verapamil administration. ( Larrousse, E; Noguera, L; Permanyer-Miralda, G; Sagristá-Sauleda, J; Soler-Soler, J; Tornos, MP, 1983) |
| ", verapamil, disopyramide, and procainamide, on paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (Af) and atrial flutter (AF) were evaluated electrophysiologically." | 3.66 | Electrophysiologic evaluation of antiarrhythmic drugs on supraventricular tachyarrhythmias. ( Hiejima, K; Satake, S; Suzuki, F; Takahashi, M, 1983) |
| "We examined the electrophysiologic effects of verapamil in eight patients with the Wolff-Parkinson-White syndrome." | 3.66 | Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. ( Carruthers, SG; Gulamhusein, S; Klein, GJ; Ko, P, 1982) |
| "The effect of verapamil on the pharmacokinetics of digoxin was studied in 49 patients with chronic atrial fibrillation." | 3.66 | The influence of verapamil on serum digoxin concentration. ( Di Segni, E; Guerrero, J; Kaplinsky, E; Klein, HO; Lang, R; Libhaber, C; Weiss, E, 1982) |
| "The elimination of verapamil and its n-demethylated metabolite, norverapamil, was studied in nine patients with chronic atrial fibrillation after the first oral verapamil dose and during chronic oral verapamil administration." | 3.66 | Prolongation of verapamil elimination kinetics during chronic oral administration. ( Harrison, DC; Kates, RE; Keefe, DL; Kirsten, E; Schwartz, JB, 1982) |
| "20 patients with atrial fibrillation and rapid ventricular response were treated with the new calcium-antagonist Gallopamil." | 3.66 | [Heart rate reduction in atrial fibrillation with a rapid ventricular response by Gallopamil, a Ca-antagonist (author's transl)]. ( Buss, J; Horn, HG; Mitrović, V; Neuss, H; Schlepper, M, 1982) |
| "The pharmacokinetic parameters and oral bioavailability of the antiarrhythmic drug verapamil were determined in six patients with atrial fibrillation." | 3.66 | Clinical pharmacokinetics of verapamil in patients with atrial fibrillation. ( Anderson, P; BondessoN, U; Sylvén, C, 1982) |
| "The effects of intravenous verapamil on the electrophysiologic properties of the accessory pathway in 12 patients with symptomatic Wolff-Parkinson-White syndrome were studied using intracardiac electrical recordings." | 3.66 | Effects of verapamil on the electrophysiologic properties of the accessory pathway in patients with the Wolff-Parkinson-White syndrome. ( Anderson, S; Federman, J; Harper, RW; Middlebrook, K; Pitt, A; Whitford, E, 1982) |
| "The effects of physical exercise, isoproterenol and atropine upon the ventricular rate and regularity were studied in 12 patients with atrial fibrillation (AF) during verapamil-induced regular ventricular rhythm." | 3.66 | Verapamil-induced ventricular regularity in atrial fibrillation. Effects of exercise, isoproterenol, atropine and conversion to sinus rhythm. ( Khalsa, A; Olsson, SB, 1979) |
| "The acute effect of verapamil on the ventricular rate in atrial fibrillation and flutter was studied in 15 patients, 13 of whom had heart rate inadequately controlled with digitalis." | 3.66 | Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter. ( Dominic, J; Kuo, CS; McAllister, RG; Reddy, CP; Surawicz, B, 1979) |
| "Personal clinical experience using Verapamil intravenously in 200 patients with a number of arrhythmia conditions is reported." | 3.65 | [Four years of clinical experience with the cardio-eurhythmic action of verapamil in intravenous administration]. ( Malfatti, S; Piccini, A, 1975) |
| "The influence of practolol or verapamil on the activity of digoxin in atrial fibrillation has been studied in 16 hospitalized patients by determining plasma levels of the cardiac glycoside and its effects on the ventricular rate, before and during the association with each of the above drugs." | 3.65 | Plasma digoxin concentrations in patients with atrial fibrillation and indications for the association with other antiarrhythmic agents. ( Cargnelli, G; Domeneghetti, F; Ferrari, M; Malacini, P; Roberti, G, 1977) |
| "The haemodynamic effect of intravenous verapamil was assessed in eight digitalised patients with atrial fibrillation, at rest and on exercise." | 3.65 | Haemodynamic effect of intravenous verapamil in controlled atrial fibrillation. ( Ramshaw, J; Sloman, G; Spokes, J; Vohra, J, 1975) |
| "Verapamil was administered intravenously to 250 patients aged between 14 and 85, suffering from tachyarrhythmia of various type." | 3.65 | [Clinical results with verapamil in intravenous administration in the emergency therapy of cardiac arrhythmias]. ( Amoroso, A, 1975) |
| "Rapid and slow venous infusion of various doses of Verapamil in a mixed series of 185 cases of arrhythmia since 1968 is reported." | 3.65 | [Anti-arrhythmic therapy with verapamil by intravenous infusion]. ( Disertori, M; Furlanello, F; Lanzetta, T; Piccolo, E; Trevi, GP, 1975) |
| "The effects of intravenous verapamil on the electrocardiogram in 15 patients with heart disease in sinus rhythm and in 44 patients with supraventricular and ventricular tachyarrhythmias were evaluated." | 3.65 | Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. ( Heng, MK; Mercer, CJ; Norris, RM; Roche, AH; Singh, BN, 1975) |
| "Verapamil administered by the intravenous route restored sinus rhythm in 33 out of 40 episodes of supraventricular tachycardia." | 3.65 | Clinical experience with verapamil. ( Hunt, D; Sloman, G; Vohra, J, 1975) |
| "Verapamil was administered by intravenous injection to 181 patients with various cardiac arrhythmias." | 3.65 | Immediate effects of intravenous verapamil in cardiac arrhythmias. ( Garrett, C; Krikler, DM; Schamroth, L, 1972) |
| "Verapamil prevented the increase in fibrillatory frequency in PAF patients in relatively long-term observation." | 2.73 | Effect of oral L-type calcium channel blocker on repetitive paroxysmal atrial fibrillation: spectral analysis of fibrillation waves in the Holter monitoring. ( Fujiki, A; Fukaya, H; Hatakeyama, Y; Izumi, T; Niwano, S; Sasaki, T, 2007) |
| " Abbreviated dosing of verapamil prior to cardioversion improves outcome at 1 week postcardioversion." | 2.72 | Signal-averaged P wave reflects change in atrial electrophysiological substrate afforded by verapamil following cardioversion from atrial fibrillation. ( Lane, J; Redfearn, DP; Skanes, AC; Stafford, PJ, 2006) |
| "In patients with persistent atrial fibrillation (AF), the efficacy and safety of two anti-arrhythmic drugs in preventing the recurrence of AF after successful direct current (DC) cardioversion was prospectively assessed in a multi-centre double-blind, placebo-controlled, randomised trial using daily trans-telephonic monitoring." | 2.71 | Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. ( Bauer, P; Breithardt, G; Engberding, R; Fetsch, T; Koch, HP; Lukl, J; Meinertz, T; Oeff, M; Seipel, L; Trappe, HJ; Treese, N, 2004) |
| "Amiodarone and verapamil have been employed to treat immediate recurrences of AF (IRAF) after cardioversion." | 2.71 | Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion. ( Behrens, S; Kamke, W; Stahn, A; Sticherling, C; Zabel, M, 2005) |
| "The indication to treat symptomatic paroxysmal atrial fibrillation is discussed controversely." | 2.69 | [Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT Study. Executive committee of the investigators representing trial physicians]. ( Koch, HP; Lüderitz, B; Meinertz, T; Patten, M; Sonntag, F, 1999) |
| " If sinus rhythm could not be established at that time, electric cardioversion was performed and the drug was continued in lower dosage thereafter." | 2.67 | [Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation--conversion and 12-month follow-up--a randomized comparison]. ( Betz, P; Kalusche, D; Roskamm, H; Stockinger, J, 1994) |
| "Propafenone is a class 1c antiarrhythmic agent that has an electrophysiologic profile suggesting that it might be potentially effective in recent-onset AF." | 2.67 | Clinical course of recent-onset atrial fibrillation treated with oral propafenone. ( Ganam, R; Ganem, R; Rabner, M; Weiner, P; Zidan, F, 1994) |
| "Verapamil caused a lower ventricular rate, but only six (19%) of the patients (n = 31) converted to sinus rhythm within 4 h (p < 0." | 2.67 | The effect of magnesium versus verapamil on supraventricular arrhythmias. ( Birkeland, K; Gullestad, L; Høyer, MM; Kjekshus, J; Mølstad, P; Vanberg, P, 1993) |
| "Antiarrhythmic therapy was chosen for 3-7 days by modified chronic electrophysiological study at three stages: (1) the efficacy of a drug, its action onset and termination were defined; (2) a dosage was chosen on an individual basis and the duration of drug potency was specified; (3) the dosage regimen of a drug given as a course therapy was confirmed by the results of trials." | 2.67 | [Evaluation of the possibility of selection of individual anti-arrhythmia therapy]. ( Antonchenko, IV; Borisova, EV; Chekhov, AM; Gimrikh, EO; Plekhanov, IG; Popov, SV; Savenkova, GM, 1991) |
| "Treatment with atenolol was associated with a marked reduction in maximum treadmill walking distance (mean 356 m) as compared both with placebo (mean 421 m, p less than 0." | 2.66 | Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. ( Lewis, RV; McDevitt, DG; McMurray, J, 1989) |
| "She had coronary atherosclerosis, liver cirrhosis and bradycardia-tachycardia syndrome." | 2.41 | Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium. ( Hattori, K; Hirakawa, Y; Ichihashi, R; Kei, M; Matsubara, K; Saburi, Y; Sakurai, H; Tsukamoto, H; Yokouchi, K, 2000) |
| " From the investigations to date, changing the digoxin dosage prior to initiating calcium antagonist therapy is, however, not justifiable." | 2.38 | [Interaction between calcium antagonists and digoxin]. ( Christensen, C, 1991) |
| "Their value in ventricular arrhythmias is uncertain but they are unlikely to be effective except in those complicating coronary artery spasms." | 2.36 | Calcium antagonists. Clinical use in the treatment of arrhythmias. ( Baky, SH; Nademanee, K; Singh, BN, 1983) |
| "Verapamil acts as an open-channel blocker of hKv1." | 1.51 | Identification of Verapamil Binding Sites Within Human Kv1.5 Channel Using Mutagenesis and Docking Simulation. ( Ding, WG; Kojima, A; Matsuura, H; Mi, X; Seto, T; Tano, A, 2019) |
| "When verapamil treatment was stopped, the patient experienced AF recurrence." | 1.51 | Treatment with verapamil for restoration of sinus rhythm in atrial fibrillation with rapid ventricular response: A case report. ( Chen, L; Liang, D; Lin, J; Lin, Y; Qi, G; Tian, W; Wang, X, 2019) |
| "In the treatment of a cardiogenic shock induced by β-blockers and/or non-dihydropyridine calcium channel blockers, administration of intravenous calcium, glucagon or high-dose insulin is recommended." | 1.43 | [Cardiogenic shock after drug therapy for atrial fibrillation with tachycardia : Case report of an 89-year-old woman]. ( Bertsch, T; Christ, M; Fey, H; Geise, AT; Jost, M, 2016) |
| "A couple of days after increasing the dosage of betaadrenergic- and adding calcium channel blockers due to an increased heart rate in atrial fibrillation, a 77 year old female was found in cardiogenic shock." | 1.38 | [The choked heart]. ( Furrer, F; Giambarba, C, 2012) |
| "Drug treatment of hypertrophic cardiomyopathy is the first-line treatment, at the onset of clinical signs and symptoms." | 1.35 | [Drug treatment for hypertrophic cardiomyopathy]. ( Gibelin, P, 2009) |
| "Verapamil did not cause a significant change either in the SN or in the PVD cycle length." | 1.33 | Response to pharmacological challenge of dissociated pulmonary vein rhythm. ( Abdul-Karim, A; Bhargava, M; Burkhardt, D; Erciyes, D; Khaykin, Y; Marrouche, N; Martin, DO; Natale, A; Rossillo, A; Saliba, W; Schweikert, R; Verma, A; Wazni, OM, 2005) |
| "Refractory cardiogenic shock has been reported after a therapeutic dose of modified release verapamil with concomitant use of beta blocker, metoprolol, but not after a single therapeutic oral dose of modified release verapamil alone." | 1.33 | Modified release verapamil induced cardiogenic shock. ( Ashish, A; Nanda, U; Why, HJ, 2005) |
| "Verapamil treatment resulted in a significant decrease in the longest pacing CL at which DA was induced (207+/-19 vs 178+/-17 ms, p<0." | 1.33 | Discordant repolarization alternans-induced atrial fibrillation is suppressed by verapamil. ( Furukawa, Y; Hiromoto, K; Kanemori, T; Masuyama, T; Mine, T; Ohyanagi, M; Shimizu, H, 2005) |
| "Verapamil is known to suppress shortening of the atrial effective refractory period (AERP) during relatively short-term atrial pacing, although the effect of a long-term stimulation model is unclear." | 1.32 | Verapamil suppresses the inhomogeneity of electrical remodeling in a canine long-term rapid atrial stimulation model. ( Inuo, K; Izumi, T; Kojima, J; Moriguchi, M; Niwano, S; Yoshizawa, N, 2003) |
| "In part V of a series of papers on epidemiology and drug prevention of stroke and other thromboembolic complications of atrial fibrillation the authors analyze data of randomized trials exhibiting ability of long term use of beta-adrenoblockers, angiotensin converting enzyme inhibitors, angiotensin receptor antagonists and statins to prevent atrial fibrillation." | 1.32 | [Stroke and other thromboembolic complications of atrial fibrillation. Part v. The use of drugs without antithrombotic or antiarrhythmic properties.]. ( Batyraliev, TA; Kiktev, VG; Pershukov, IV; Preobrazhenskiĭ, DV; Sidorenko, BA, 2004) |
| "Verapamil was administered at a loading dose of 0." | 1.31 | Profibrillatory effects of verapamil but not of digoxin in the goat model of atrial fibrillation. ( Allessie, MA; Duytschaever, MF; Garratt, CJ, 2000) |
| "Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem." | 1.31 | Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs. ( Bénardeau, A; Fareh, S; Nattel, S, 2001) |
| "The emergency physician diagnosed a cardiac arrest." | 1.30 | [Torsade de pointes tachycardia during administration of quinidine and verapamil in atrial fibrillation]. ( Karch, M; Plewan, A; Schmidt, G; Schmitt, C; Schömig, A, 1997) |
| " R56865 was given before ischemia and with the onset of reperfusion, applying different dosing schedules, including an initial loading dose." | 1.29 | R56865 is antifibrillatory in reperfused ischemic guinea-pig hearts, even when given only during reperfusion. ( Guttmann, I; Mozes, A; Scheufler, E; Wilffert, B, 1995) |
| "The case of a patient with idiopathic dilated cardiomyopathy and complex ventricular arrhythmias who underwent placement of an automatic implantable cardioverter-defibrillator (AICD) and experienced inappropriate shocks during atrial fibrillation is presented." | 1.28 | Emergency department management of patients with automatic implantable cardioverter-defibrillators. ( Craig, SA; Hudson, AD, 1990) |
| "Verapamil may cause detrimental results when given to patients with the Wolff-Parkinson-White syndrome and atrial fibrillation." | 1.28 | Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation. ( Agmon, J; Katz, A; Ovsyscher, IA; Rechavia, E; Sagie, A; Sclarovsky, S; Strasberg, B, 1989) |
| "When amiodarone was not employed, as a first choice, in conformity with a specific protocol, it was utilized as a second choice after verapamil or flecainide." | 1.28 | [Supraventricular tachyarrhythmia of recent onset in the absence of documented cardiac pathology: different therapeutic approaches]. ( Bechi, S; Cordoni, M; Franchini, C; Mazza, F; Micheli, G; Scalzini, A, 1989) |
| "The mechanisms underlying the cause of sudden death have not been clearly elucidated." | 1.27 | [Arrhythmias in hypertrophic cardiomyopathy. Significance and therapeutic consequences]. ( Kleinebenne, A; McKenna, WJ, 1985) |
| " Trough serum concentration of verapamil did not differ during the two dosage regimens (59 ng/ml - conventional formulation and 49." | 1.27 | 24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation. ( Bjerregaard, P; Jørgensen, HS; Klitgaard, NA; Mølgaard, H, 1987) |
| "Calcium-channel blockers are useful for the treatment of hypertrophic cardiomyopathy (HCM), but, their adverse effects, especially, those of diltiazem, have not been of much concern." | 1.27 | Adverse effects of atrial fibrillation and syncope induced by calcium-channel blockers in hypertrophic cardiomyopathy. ( Doiuchi, J; Hamada, M; Ito, T; Kokubu, T; Ochi, T, 1985) |
| "In 65% of the 23 cases with atrial extrasystoles or atrial tachycardias a significant reduction of the ectopics could be achieved or a regular sinus rhythm could be established." | 1.26 | [Combination treatment of atrial arrhythmias with quinidine-verapamil]. ( Bramann, HU; Brisse, B; Gülker, H; Kuhs, H, 1980) |
| "Verapamil disposition was studied in 12 patients with chronic and fibrillation." | 1.26 | Verapamil disposition kinetics in chronic atrial fibrillation. ( Harapat, S; Harrison, DC; Kates, RE; Keefe, DL; Kirsten, EB; Schwartz, J, 1981) |
| "Verapamil is a novel antiarrhythmic agent which appears to act as a calcium-ion antagonist, blocking calcium transport across the myocardial cell membrane." | 1.25 | [Verapamil in the study and treatment of supraventricular tachycardias, with special reference to pre-excitation]. ( Krikler, DM, 1975) |
| "Verapamil was administered i." | 1.25 | [Venous infusion of nerapamil in the treatment of refractory angina pectoris and arrhythmia due to associated electric instability]. ( Furlanello, F; Lanzetta, T; Pascotto, P; Piccolo, E; Trevi, GP, 1975) |
| "In this age group most of the occurring cardiac arrhythmias are harmless and pass without serious circulatory disturbances." | 1.25 | [Treatment of heart-rhythm disorders in infancy and childhood]. ( Eschenbacher, HL; Gutheil, H; Singer, H, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 194 (51.46) | 18.7374 |
| 1990's | 73 (19.36) | 18.2507 |
| 2000's | 81 (21.49) | 29.6817 |
| 2010's | 19 (5.04) | 24.3611 |
| 2020's | 10 (2.65) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, AP | 1 |
| Hohnloser, SH | 1 |
| Bannister, BE | 1 |
| Parry, DR | 1 |
| Pouliot, JD | 1 |
| Editorial, A | 1 |
| Komatsu, Y | 1 |
| Yodoshi, M | 1 |
| Takegami, M | 1 |
| Yokoyama, S | 1 |
| Hosomi, K | 1 |
| Meyer, M | 1 |
| Wetmore, JB | 1 |
| Weinhandl, ED | 1 |
| Roetker, NS | 1 |
| Orso, D | 1 |
| Santangelo, S | 1 |
| Guglielmo, N | 1 |
| Bove, T | 1 |
| Cilenti, F | 1 |
| Cristiani, L | 1 |
| Copetti, R | 1 |
| Cheong, EJY | 1 |
| Teo, DWX | 1 |
| Chua, DXY | 1 |
| Chan, ECY | 1 |
| Pham, P | 1 |
| Schmidt, S | 1 |
| Lesko, L | 1 |
| Lip, GYH | 1 |
| Brown, JD | 1 |
| Rajput, FA | 1 |
| Du, L | 1 |
| Chappell, RJ | 1 |
| Berei, TJ | 1 |
| Goldberger, ZD | 1 |
| Wright, JM | 1 |
| Arai, R | 1 |
| Fukamachi, D | 1 |
| Monden, M | 1 |
| Akutsu, N | 1 |
| Murata, N | 1 |
| Okumura, Y | 1 |
| Sychev, D | 1 |
| Mirzaev, K | 1 |
| Cherniaeva, M | 1 |
| Kulikova, M | 1 |
| Bochkov, P | 1 |
| Shevchenko, R | 1 |
| Gorbatenkova, S | 1 |
| Golovina, O | 1 |
| Ostroumova, O | 1 |
| Bahteeva, D | 1 |
| Rytkin, E | 1 |
| Washam, JB | 1 |
| Hellkamp, AS | 1 |
| Lokhnygina, Y | 1 |
| Piccini, JP | 1 |
| Berkowitz, SD | 1 |
| Nessel, CC | 1 |
| Becker, RC | 1 |
| Breithardt, G | 3 |
| Fox, KAA | 1 |
| Halperin, JL | 1 |
| Hankey, GJ | 1 |
| Mahaffey, KW | 1 |
| Singer, DE | 1 |
| Patel, MR | 1 |
| Abu-Amer, N | 1 |
| Priel, E | 1 |
| Karlish, SJD | 1 |
| Farfel, Z | 1 |
| Mayan, H | 2 |
| Ding, WG | 1 |
| Tano, A | 1 |
| Mi, X | 1 |
| Kojima, A | 1 |
| Seto, T | 1 |
| Matsuura, H | 1 |
| Wang, X | 1 |
| Lin, Y | 1 |
| Chen, L | 1 |
| Liang, D | 1 |
| Lin, J | 1 |
| Qi, G | 1 |
| Tian, W | 1 |
| Ulimoen, SR | 4 |
| Enger, S | 4 |
| Pripp, AH | 2 |
| Abdelnoor, M | 2 |
| Arnesen, H | 3 |
| Gjesdal, K | 2 |
| Tveit, A | 4 |
| Norseth, J | 2 |
| Khori, V | 1 |
| Alizadeh, AM | 1 |
| Moheimani, HR | 1 |
| Zahedi, M | 1 |
| Aminolsharieh Najafi, S | 1 |
| Shakiba, D | 1 |
| Nayebpour, M | 1 |
| Corino, VD | 1 |
| Mainardi, LT | 1 |
| Platonov, PG | 2 |
| Fey, H | 1 |
| Jost, M | 1 |
| Geise, AT | 1 |
| Bertsch, T | 1 |
| Christ, M | 1 |
| Horjen, AW | 1 |
| Seljeflot, I | 1 |
| Gibelin, P | 1 |
| Raatikainen, MJ | 1 |
| Kushiyama, Y | 1 |
| Osaka, T | 1 |
| Yokoyama, E | 1 |
| Hasebe, H | 1 |
| Kuroda, Y | 1 |
| Kamiya, K | 1 |
| Kodama, I | 1 |
| Climent, AM | 1 |
| Guillem, MS | 1 |
| Husser, D | 1 |
| Castells, F | 1 |
| Millet, J | 1 |
| Bollmann, A | 2 |
| Shah, DP | 1 |
| Baez-Escudero, JL | 1 |
| Weisberg, IL | 1 |
| Beshai, JF | 1 |
| Burke, MC | 1 |
| Yagishita, A | 1 |
| Hachiya, H | 1 |
| Nakamura, T | 1 |
| Sugiyama, K | 1 |
| Tanaka, Y | 1 |
| Sasano, T | 1 |
| Kawabata, M | 1 |
| Isobe, M | 1 |
| Hirao, K | 1 |
| Furrer, F | 1 |
| Giambarba, C | 1 |
| Sacha, J | 1 |
| Barabach, S | 1 |
| Feusette, P | 1 |
| Kukla, P | 1 |
| Apel, A | 1 |
| Rachel, P | 1 |
| Cohen, O | 1 |
| Niwano, S | 5 |
| Freestone, B | 4 |
| Kamath, S | 2 |
| Lip, G | 2 |
| Sticherling, C | 3 |
| Ozaydin, M | 1 |
| Tada, H | 2 |
| Oral, H | 4 |
| Pelosi, F | 4 |
| Knight, BP | 6 |
| Strickberger, SA | 6 |
| Morady, F | 6 |
| Vecht, RJ | 1 |
| Bertaglia, E | 3 |
| D'Este, D | 2 |
| Zerbo, F | 2 |
| Michieletto, M | 1 |
| Pascotto, P | 3 |
| Hassan, SA | 1 |
| Scharf, C | 1 |
| Chugh, A | 1 |
| Martinelli, MM | 1 |
| Dragagna, G | 1 |
| Vitali, A | 1 |
| Fedele, F | 1 |
| Favale, S | 1 |
| Pappone, C | 1 |
| Nacci, F | 1 |
| Fino, F | 1 |
| Resta, F | 1 |
| Dicandia, CD | 1 |
| Fedorov, VV | 1 |
| Glukhov, AV | 1 |
| Sharifov, OF | 1 |
| Beloshapko, GG | 1 |
| Iushmanova, AV | 1 |
| Rozenshtraukh, LV | 1 |
| Popov, SV | 2 |
| Kandinskiĭ, ML | 1 |
| Kozlov, BN | 1 |
| Antonchenko, IV | 2 |
| Evtushenko, AV | 1 |
| Dzhavadova, GK | 1 |
| Vecherskiĭ, IuIu | 1 |
| Akhmedov, ShD | 1 |
| Afanas'ev, SA | 1 |
| Shipulin, VM | 1 |
| De Simone, A | 3 |
| De Pasquale, M | 1 |
| De Matteis, C | 3 |
| Canciello, M | 1 |
| Manzo, M | 1 |
| Sabino, L | 1 |
| Alfano, F | 1 |
| Di Mauro, M | 1 |
| Campana, A | 1 |
| De Fabrizio, G | 1 |
| Vitale, DF | 2 |
| Turco, P | 3 |
| Stabile, G | 3 |
| Scherer, M | 1 |
| Dzemali, O | 1 |
| Aybek, T | 1 |
| Wimmer-Greinecker, G | 1 |
| Moritz, A | 1 |
| Maron, BJ | 2 |
| McKenna, WJ | 3 |
| Danielson, GK | 1 |
| Kappenberger, LJ | 1 |
| Kuhn, HJ | 1 |
| Seidman, CE | 2 |
| Shah, PM | 1 |
| Spencer, WH | 1 |
| Spirito, P | 2 |
| Ten Cate, FJ | 1 |
| Wigle, ED | 1 |
| Moriguchi, M | 1 |
| Yoshizawa, N | 1 |
| Kojima, J | 1 |
| Inuo, K | 1 |
| Izumi, T | 2 |
| Khan, IA | 2 |
| Sung, RJ | 3 |
| Mafrici, A | 1 |
| Alberti, A | 1 |
| Corrada, E | 1 |
| Ferrari, S | 1 |
| Marenna, B | 1 |
| Tamariz, LJ | 1 |
| Bass, EB | 2 |
| Nedostup, AV | 1 |
| Blagova, OV | 1 |
| Bogdanova, EA | 1 |
| Platonova, AA | 1 |
| Lindholm, CJ | 2 |
| Fredholm, O | 1 |
| Möller, SJ | 1 |
| Edvardsson, N | 1 |
| Kronvall, T | 1 |
| Pettersson, T | 1 |
| Firsovaite, V | 1 |
| Roijer, A | 2 |
| Meurling, CJ | 2 |
| Olsson, SB | 4 |
| Merckx, KL | 1 |
| Tieleman, RG | 3 |
| Crijns, HJ | 4 |
| Fetsch, T | 3 |
| Bauer, P | 1 |
| Engberding, R | 2 |
| Koch, HP | 3 |
| Lukl, J | 2 |
| Meinertz, T | 5 |
| Oeff, M | 1 |
| Seipel, L | 2 |
| Trappe, HJ | 3 |
| Treese, N | 2 |
| Basu Ray, I | 1 |
| Ohashi, N | 1 |
| Mitamura, H | 2 |
| Tanimoto, K | 1 |
| Fukuda, Y | 1 |
| Kinebuchi, O | 2 |
| Kurita, Y | 2 |
| Shiroshita-Takeshita, A | 2 |
| Miyoshi, S | 2 |
| Hara, M | 2 |
| Takatsuki, S | 2 |
| Ogawa, S | 2 |
| Lip, GY | 3 |
| Preobrazhenskiĭ, DV | 1 |
| Sidorenko, BA | 1 |
| Kiktev, VG | 1 |
| Batyraliev, TA | 1 |
| Pershukov, IV | 1 |
| Marrouche, N | 1 |
| Wazni, OM | 1 |
| Martin, DO | 1 |
| Rossillo, A | 1 |
| Saliba, W | 1 |
| Erciyes, D | 1 |
| Schweikert, R | 1 |
| Khaykin, Y | 1 |
| Burkhardt, D | 1 |
| Bhargava, M | 1 |
| Verma, A | 1 |
| Abdul-Karim, A | 1 |
| Natale, A | 2 |
| Veloso, HH | 1 |
| de Paola, AA | 1 |
| Nitschmann, S | 1 |
| Antz, M | 1 |
| Kuck, KH | 1 |
| Liu, J | 1 |
| Huang, CX | 1 |
| Bao, MW | 1 |
| Wang, T | 1 |
| Boriani, G | 1 |
| Carboni, A | 1 |
| Latini, R | 1 |
| Biffi, M | 1 |
| Martignani, C | 1 |
| Sciotto, F | 1 |
| Branzi, A | 1 |
| Behrens, S | 1 |
| Kamke, W | 1 |
| Stahn, A | 1 |
| Zabel, M | 1 |
| Nanda, U | 1 |
| Ashish, A | 1 |
| Why, HJ | 1 |
| Hiromoto, K | 1 |
| Shimizu, H | 1 |
| Furukawa, Y | 1 |
| Kanemori, T | 1 |
| Mine, T | 1 |
| Masuyama, T | 1 |
| Ohyanagi, M | 1 |
| Malik, A | 1 |
| Ali, SS | 1 |
| Rahmatullah, A | 1 |
| Leaver, SK | 1 |
| Ho, TB | 1 |
| Borja, J | 1 |
| Izquierdo, I | 1 |
| Guindo, J | 2 |
| Tsuneda, T | 1 |
| Yamashita, T | 1 |
| Fukunami, M | 1 |
| Kumagai, K | 2 |
| Okumura, K | 1 |
| Inoue, H | 1 |
| Hemels, ME | 1 |
| Van Noord, T | 2 |
| Van Veldhuisen, DJ | 1 |
| Veeger, NJ | 2 |
| Bosker, HA | 2 |
| Wiesfeld, AC | 1 |
| Van den Berg, MP | 1 |
| Ranchor, AV | 1 |
| Van Gelder, IC | 3 |
| Patten, M | 2 |
| Maas, R | 1 |
| Karim, A | 1 |
| Müller, HW | 1 |
| Simonovsky, R | 1 |
| Redfearn, DP | 1 |
| Skanes, AC | 1 |
| Lane, J | 1 |
| Stafford, PJ | 1 |
| Kao, SL | 1 |
| Ooi, S | 1 |
| Hirose, M | 1 |
| Laurita, KR | 1 |
| Fukaya, H | 1 |
| Sasaki, T | 1 |
| Hatakeyama, Y | 1 |
| Fujiki, A | 1 |
| Dhein, S | 1 |
| Duerrschmidt, N | 1 |
| Scholl, A | 1 |
| Boldt, A | 1 |
| Schulte, JS | 1 |
| Pfannmüller, B | 1 |
| Rojas-Gomez, D | 1 |
| Scheffler, A | 1 |
| Haefliger, JA | 1 |
| Doll, N | 1 |
| Mohr, FW | 1 |
| Yildiz, A | 1 |
| Yigit, Z | 1 |
| Okcun, B | 1 |
| Baskurt, M | 1 |
| Ortak, K | 1 |
| Kaya, A | 1 |
| Kucukoglu, S | 1 |
| Peters, RW | 1 |
| Leclercq, JF | 1 |
| Georgiopoulos, G | 1 |
| Halkidis, H | 1 |
| Attuel, P | 1 |
| Maisonblanche, P | 1 |
| Coumel, P | 1 |
| Theisen, K | 2 |
| Prystowsky, EN | 2 |
| Lander, R | 1 |
| Willoughby, ML | 1 |
| Dunlap, DB | 1 |
| Gmeiner, R | 1 |
| Sterz, H | 1 |
| Gülker, H | 2 |
| Bramann, HU | 1 |
| Brisse, B | 2 |
| Kuhs, H | 1 |
| Bender, F | 6 |
| Heuer, H | 1 |
| Thale, J | 1 |
| Frishman, WH | 1 |
| LeJemtel, TH | 1 |
| von Bock, U | 1 |
| Sloan, RW | 1 |
| Zipes, DP | 3 |
| Gilmour, RF | 2 |
| Lang, R | 3 |
| Klein, HO | 6 |
| Weiss, E | 3 |
| David, D | 3 |
| Sareli, P | 2 |
| Levy, A | 1 |
| Guerrero, J | 4 |
| Di Segni, E | 4 |
| Kaplinsky, E | 6 |
| Singh, BN | 3 |
| Nademanee, K | 2 |
| Baky, SH | 1 |
| Petri, H | 1 |
| Kafka, W | 1 |
| Rudolph, W | 1 |
| Feld, G | 1 |
| Panidis, IP | 1 |
| Morganroth, J | 1 |
| Baessler, C | 1 |
| Vlay, SC | 1 |
| Reid, PR | 1 |
| Dick, M | 1 |
| Campbell, RM | 1 |
| Klein, GJ | 2 |
| Twum-Barima, Y | 1 |
| Gulamhusein, S | 2 |
| Carruthers, SG | 2 |
| Donner, AP | 1 |
| Perrot, B | 1 |
| Danchin, N | 1 |
| Terrier de la Chaise, A | 1 |
| Weinrauch, LA | 1 |
| Belok, S | 1 |
| D'Elia, JA | 1 |
| Nissen, MB | 1 |
| Lemberg, L | 1 |
| Scheininger, M | 1 |
| Maier, WD | 1 |
| Neuss, H | 3 |
| Bilgin, Y | 1 |
| Gigler, G | 1 |
| Thormann, J | 2 |
| Schlepper, M | 3 |
| Waldo, AL | 2 |
| Plumb, VJ | 2 |
| Arciniegas, JG | 1 |
| Henthorn, RW | 1 |
| Zimmern, SH | 1 |
| Tommaso, C | 1 |
| McDonough, T | 1 |
| Parker, M | 1 |
| Talano, JV | 1 |
| Hwang, MH | 1 |
| Danoviz, J | 1 |
| Pacold, I | 1 |
| Rad, N | 1 |
| Loeb, HS | 1 |
| Gunnar, RM | 1 |
| Johansson, PA | 1 |
| Golling, FR | 1 |
| Weissmüller, P | 1 |
| Kindler, M | 1 |
| Penkov, N | 1 |
| Penev, A | 1 |
| Kaponov, Kh | 1 |
| Vohra, J | 3 |
| Bar-Or, D | 1 |
| Gasiel, Y | 1 |
| Sapire, DW | 1 |
| O'Riordan, AC | 1 |
| Black, IF | 1 |
| Beck, OA | 1 |
| Günther, R | 1 |
| Hochrein, H | 1 |
| Soler-Soler, J | 1 |
| Permanyer-Miralda, G | 1 |
| Sagristá-Sauleda, J | 1 |
| Noguera, L | 1 |
| Larrousse, E | 1 |
| Tornos, MP | 1 |
| Hiejima, K | 1 |
| Suzuki, F | 1 |
| Takahashi, M | 1 |
| Satake, S | 1 |
| Kopman, EA | 1 |
| Uzilevskaia, RA | 1 |
| Grishkin, IuN | 1 |
| Gefen, J | 1 |
| Libhaber, C | 2 |
| Wu, D | 1 |
| Rowland, TW | 1 |
| Schwartz, JB | 3 |
| Schamroth, L | 3 |
| Aronow, WS | 3 |
| Ferlinz, J | 2 |
| Waxman, HL | 2 |
| Elser, B | 1 |
| Juma, Z | 1 |
| Follath, F | 1 |
| Fromer, M | 2 |
| Meier, P | 1 |
| Vozeh, S | 1 |
| Rasmussen, K | 1 |
| Wang, H | 1 |
| Fausa, D | 1 |
| Gonzalez, R | 1 |
| Scheinman, MM | 1 |
| Karp, RB | 1 |
| Kouchoukos, NT | 1 |
| Zorn, GL | 1 |
| James, TN | 1 |
| Ko, P | 1 |
| Stern, EH | 1 |
| Pitchon, R | 1 |
| King, BD | 1 |
| Schneider, RR | 1 |
| Wiener, I | 1 |
| Lipman, J | 1 |
| Jardine, I | 1 |
| Roos, C | 1 |
| Dreosti, L | 1 |
| Keefe, D | 1 |
| Kates, RE | 3 |
| Kirsten, E | 2 |
| Harrison, DC | 3 |
| Noble, RJ | 1 |
| Steinmetz, EF | 1 |
| Hillis, JS | 1 |
| Rothbaum, DA | 1 |
| Hallam, CC | 1 |
| Landin, RJ | 1 |
| Keefe, DL | 3 |
| Santo, M | 1 |
| Aderka, D | 1 |
| Pinkhas, J | 1 |
| Horn, HG | 1 |
| Mitrović, V | 1 |
| Buss, J | 1 |
| Anderson, P | 2 |
| BondessoN, U | 1 |
| Sylvén, C | 1 |
| Oliveros, RA | 1 |
| Kruyer, WB | 1 |
| Chilton, RJ | 1 |
| Beckmann, CH | 1 |
| Boran, KJ | 1 |
| Harper, RW | 1 |
| Whitford, E | 1 |
| Middlebrook, K | 1 |
| Federman, J | 1 |
| Anderson, S | 1 |
| Pitt, A | 1 |
| Schwartz, J | 1 |
| Harapat, S | 1 |
| Kirsten, EB | 1 |
| Kleinebenne, A | 2 |
| Mannebach, H | 1 |
| Gleichmann, U | 2 |
| Di Michele, R | 1 |
| Bertoni, PD | 1 |
| Tosetto, C | 1 |
| Rabkin, SW | 1 |
| Tomlinson, C | 1 |
| Corbett, BN | 1 |
| Cuddy, TE | 1 |
| Rinkenberger, RL | 1 |
| Heger, JJ | 1 |
| Troup, PJ | 1 |
| Jackman, WM | 1 |
| Wang, R | 1 |
| Camm, J | 1 |
| Ward, D | 3 |
| Washington, H | 1 |
| Martin, A | 1 |
| Myerburg, RJ | 2 |
| Appel, R | 1 |
| Scimone, IM | 1 |
| Oreto, G | 1 |
| Consolo, A | 1 |
| Pulitanò, G | 1 |
| Marafioti, V | 1 |
| Carbonieri, E | 1 |
| Zardini, P | 1 |
| Heywood, JT | 1 |
| Ben Zemenick, R | 2 |
| Matsuo, K | 1 |
| Ono, M | 1 |
| Yamanouchi, Y | 1 |
| Moroe, K | 1 |
| Hamasaki, N | 1 |
| Arakawa, K | 1 |
| Zehender, M | 2 |
| Just, H | 2 |
| Kalusche, D | 1 |
| Stockinger, J | 1 |
| Betz, P | 1 |
| Roskamm, H | 1 |
| Shettigar, UR | 1 |
| Fort, S | 1 |
| Lewis, MJ | 1 |
| Luscombe, DK | 1 |
| John, DN | 1 |
| Isomoto, S | 1 |
| Shimizu, A | 1 |
| Konoe, A | 1 |
| Tanigawa, M | 1 |
| Kaibara, M | 1 |
| Centurion, OA | 1 |
| Fukatani, M | 1 |
| Yano, K | 1 |
| Weiner, P | 1 |
| Ganam, R | 1 |
| Ganem, R | 1 |
| Zidan, F | 1 |
| Rabner, M | 1 |
| Van Mieghem, W | 2 |
| Coolen, L | 1 |
| Malysse, I | 1 |
| Lacquet, LM | 1 |
| Deneffe, GJ | 1 |
| Demedts, MG | 1 |
| Manz, M | 1 |
| Lüderitz, B | 2 |
| Carmona, J | 1 |
| Amado, P | 1 |
| Castanheira, J | 1 |
| Nazaré, J | 1 |
| Araújo, V | 1 |
| Gullestad, L | 1 |
| Birkeland, K | 1 |
| Mølstad, P | 1 |
| Høyer, MM | 1 |
| Vanberg, P | 1 |
| Kjekshus, J | 1 |
| Scheufler, E | 1 |
| Mozes, A | 1 |
| Guttmann, I | 1 |
| Wilffert, B | 1 |
| Blackshear, JL | 1 |
| Kopecky, SL | 1 |
| Litin, SC | 1 |
| Safford, RE | 1 |
| Hammill, SC | 1 |
| Tits, G | 1 |
| Demuynck, K | 1 |
| Lacquet, L | 1 |
| Deneffe, G | 1 |
| Tjandra-Maga, T | 1 |
| Demedts, M | 1 |
| Chen, SA | 4 |
| Chiang, CE | 1 |
| Tai, CT | 3 |
| Lee, SH | 3 |
| Chiou, CW | 1 |
| Ueng, KC | 1 |
| Wen, ZC | 1 |
| Cheng, CC | 1 |
| Chang, MS | 3 |
| Leistad, E | 1 |
| Aksnes, G | 1 |
| Verburg, E | 1 |
| Christensen, G | 1 |
| Gardner, MJ | 1 |
| Gilbert, M | 1 |
| Shimoni, A | 1 |
| Maor-Kendler, Y | 1 |
| Neuman, Y | 1 |
| Joshi, PP | 1 |
| Deshmukh, PK | 1 |
| Salkar, RG | 1 |
| Herbert, ME | 1 |
| Votey, SR | 1 |
| Rutz, F | 1 |
| Goette, A | 1 |
| Honeycutt, C | 1 |
| Langberg, JJ | 1 |
| Innes, GD | 1 |
| Vertesi, L | 1 |
| Dillon, EC | 1 |
| Metcalfe, C | 1 |
| Pfitzner, P | 1 |
| De Langen, C | 1 |
| de Kam, PJ | 1 |
| Grandjean, J | 1 |
| Bel, KJ | 1 |
| Wijffels, MC | 1 |
| Allessie, MA | 2 |
| Karch, M | 1 |
| Schmitt, C | 1 |
| Plewan, A | 1 |
| Schmidt, G | 1 |
| Schömig, A | 1 |
| Daoud, EG | 3 |
| Weiss, R | 1 |
| Bahu, M | 1 |
| Paladino, W | 1 |
| Goyal, R | 2 |
| Man, KC | 2 |
| Iagenskiĭ, VA | 1 |
| Grosu, AA | 1 |
| Orlov, YS | 1 |
| Brodsky, MA | 1 |
| Orlov, MV | 1 |
| Allen, B | 1 |
| Shepard, RK | 1 |
| Stambler, BS | 1 |
| Wood, MA | 2 |
| Gilligan, DM | 1 |
| Ellenbogen, KA | 1 |
| Yu, WC | 3 |
| Feng, AN | 1 |
| Kuo, BI | 1 |
| Ding, YA | 2 |
| Botto, GL | 1 |
| Bonini, W | 1 |
| Broffoni, T | 1 |
| Sarubbi, B | 1 |
| Ducceschi, V | 1 |
| D'Andrea, A | 1 |
| Liccardo, B | 1 |
| Santangelo, L | 1 |
| Iacono, A | 1 |
| Myers, MG | 1 |
| Alnemri, K | 1 |
| Caponi, D | 1 |
| Sykes, AM | 1 |
| Wenger, EJ | 1 |
| Khalighi, K | 1 |
| Haft, JI | 2 |
| Sonntag, F | 1 |
| Burschel, G | 1 |
| Marcovitz, P | 1 |
| Armstrong, WF | 1 |
| Friedman, HS | 1 |
| Rodney, E | 1 |
| Sinha, B | 1 |
| Sharafkhaneh, A | 1 |
| Wattanasuwan, N | 1 |
| Win, M | 1 |
| Mallipeddi, D | 1 |
| Sinha, A | 1 |
| Hussain, A | 1 |
| Dai, CP | 1 |
| Di Stasio, M | 1 |
| Petrazzuoli, F | 1 |
| Gasparini, M | 1 |
| Rotunno, R | 2 |
| Di Napoli, T | 1 |
| Hsieh, MH | 1 |
| Tsai, CF | 1 |
| Prakash, VS | 1 |
| Hsu, TL | 1 |
| Segal, JB | 1 |
| McNamara, RL | 1 |
| Miller, MR | 1 |
| Kim, N | 1 |
| Goodman, SN | 1 |
| Powe, NR | 1 |
| Robinson, K | 1 |
| Yu, D | 1 |
| Mazzone, C | 1 |
| Pandullo, C | 1 |
| Scardi, S | 1 |
| Salvi, R | 1 |
| Miccio, M | 1 |
| Cattarini, G | 1 |
| Morgera, T | 1 |
| Naccarelli, GV | 1 |
| Dell'Orfano, JT | 1 |
| Wolbrette, DL | 1 |
| Patel, HM | 1 |
| Luck, JC | 1 |
| Trohman, RG | 2 |
| Hummel, JD | 1 |
| Augostini, R | 1 |
| Williams, S | 1 |
| Kalbfleisch, SJ | 1 |
| Sakurai, H | 1 |
| Kei, M | 1 |
| Matsubara, K | 1 |
| Yokouchi, K | 1 |
| Hattori, K | 1 |
| Ichihashi, R | 1 |
| Hirakawa, Y | 1 |
| Tsukamoto, H | 1 |
| Saburi, Y | 1 |
| Pandozi, C | 2 |
| Bianconi, L | 1 |
| Calò, L | 1 |
| Castro, A | 1 |
| Lamberti, F | 1 |
| Scianaro, MC | 1 |
| Gentilucci, G | 1 |
| Santini, M | 2 |
| Lévy, S | 1 |
| Duytschaever, MF | 1 |
| Garratt, CJ | 1 |
| Tse, HF | 2 |
| Zarse, M | 1 |
| Stellbrink, C | 1 |
| Athanatou, E | 1 |
| Robert, J | 1 |
| Schotten, U | 1 |
| Hanrath, P | 1 |
| Ingemansson, MP | 1 |
| Carlson, J | 1 |
| Smideberg, B | 1 |
| Sornmo, L | 1 |
| Stridh, M | 1 |
| Bénardeau, A | 1 |
| Fareh, S | 1 |
| Nattel, S | 1 |
| Ramanna, H | 1 |
| Elvan, A | 1 |
| Wittkampf, FH | 1 |
| de Bakker, JM | 1 |
| Hauer, RN | 1 |
| Robles de Medina, EO | 1 |
| Zanocco, A | 1 |
| Busse, D | 1 |
| Fromm, MF | 1 |
| Mörike, K | 1 |
| Drescher, S | 1 |
| Kühlkamp, V | 1 |
| Eichelbaum, M | 2 |
| Wang, Q | 1 |
| Yu, CM | 1 |
| Ayers, GM | 1 |
| Lau, CP | 1 |
| Michelucci, A | 1 |
| Lazzeri, C | 1 |
| Padeletti, L | 1 |
| Bagliani, G | 1 |
| Colella, A | 1 |
| Sabini, A | 1 |
| Zipoli, R | 1 |
| Costoli, A | 1 |
| Pieragnoli, P | 1 |
| Gensini, GF | 1 |
| Franchi, F | 1 |
| Tuinenburg, AE | 1 |
| Volkers, C | 1 |
| Simpson, CS | 1 |
| Ghali, WA | 1 |
| Sanfilippo, AJ | 1 |
| Moritz, S | 1 |
| Abdollah, H | 1 |
| Zardo, F | 1 |
| Antonini-Canterin, F | 1 |
| Brieda, M | 1 |
| Hrovatin, E | 1 |
| Pavan, D | 1 |
| Burelli, C | 1 |
| Cervesato, E | 1 |
| Nicolosi, GL | 1 |
| Kodama-Takahashi, K | 1 |
| Ohshima, K | 1 |
| Yamamoto, K | 1 |
| Iwata, T | 1 |
| Laine, K | 1 |
| Valavaara, R | 1 |
| Rouru, J | 1 |
| Hsu, W | 1 |
| Bares, AC | 1 |
| Minish, T | 1 |
| Herd, A | 1 |
| Hoffmann, E | 1 |
| Janko, S | 1 |
| Reithmann, C | 1 |
| Steinbeck, G | 1 |
| Sonne, K | 1 |
| Esperer, HD | 1 |
| Toepffer, I | 1 |
| Klein, HU | 1 |
| Yamane, A | 1 |
| Ieda, M | 1 |
| Sato, T | 1 |
| La Rocca, V | 1 |
| Nocerino, P | 1 |
| Greco, L | 1 |
| Astarita, C | 1 |
| Messina, V | 1 |
| Iaconelli, G | 1 |
| Stabile, E | 1 |
| Puletti, M | 1 |
| Curione, M | 1 |
| Donaldson, RM | 1 |
| Smolenskiĭ, VS | 1 |
| Fomina, IG | 2 |
| Ankhimiuk, ON | 1 |
| Dubrova, DM | 1 |
| Iankin, VV | 2 |
| Kukes, VG | 1 |
| Kniazev, MD | 1 |
| Borovkov, AI | 1 |
| Semenov, VN | 1 |
| Mamedova, AD | 1 |
| Piccini, A | 1 |
| Malfatti, S | 1 |
| Klein, W | 1 |
| Krikler, DM | 3 |
| Marsocci, G | 1 |
| Giordano, F | 1 |
| Manai, L | 1 |
| Todini, AR | 1 |
| Artizzu, G | 1 |
| De Benedictis, F | 1 |
| Donnangelo, L | 1 |
| Sica, G | 1 |
| Ghidichimo, G | 1 |
| Vohra, JK | 1 |
| Agner, E | 1 |
| Jans, H | 1 |
| Khalsa, A | 2 |
| Olsson, B | 1 |
| Henriksson, BA | 1 |
| Csapo, G | 1 |
| Pauzner, H | 1 |
| Golitsyn, SP | 1 |
| Sokolov, SF | 1 |
| Mazur, NA | 1 |
| Stessman, J | 1 |
| Bassan, MM | 1 |
| Landa, D | 1 |
| Plasencia, G | 1 |
| Wong, R | 1 |
| Karlsberg, RP | 1 |
| Dominic, J | 1 |
| McAllister, RG | 1 |
| Kuo, CS | 1 |
| Reddy, CP | 1 |
| Surawicz, B | 1 |
| Zhang, HX | 1 |
| Zhang, LG | 1 |
| Wu, J | 1 |
| Liang, ZG | 1 |
| Kuruvilla, A | 1 |
| Subramaniam, N | 1 |
| Abraham, KA | 2 |
| Stephen, P | 1 |
| Cherian, G | 2 |
| Basu, B | 1 |
| Carvalho, MA | 1 |
| Osterne, EC | 1 |
| Bezerra, FA | 1 |
| Carvalho, PR | 1 |
| Barros, RB | 1 |
| Carneiro, RD | 1 |
| de Mendonça, JV | 1 |
| Farup, PG | 1 |
| Cargnelli, G | 1 |
| Domeneghetti, F | 1 |
| Ferrari, M | 1 |
| Malacini, P | 1 |
| Roberti, G | 1 |
| Kaufmann, G | 2 |
| Aberg, H | 1 |
| Furberg, B | 1 |
| Nordgren, L | 1 |
| Sloman, G | 2 |
| Spokes, J | 1 |
| Ramshaw, J | 1 |
| Rosen, MR | 1 |
| Wit, AL | 1 |
| Hoffman, BF | 1 |
| Piccolo, E | 2 |
| Furlanello, F | 2 |
| Trevi, GP | 2 |
| Lanzetta, T | 2 |
| Amoroso, A | 1 |
| Disertori, M | 1 |
| Heng, MK | 1 |
| Roche, AH | 1 |
| Norris, RM | 1 |
| Mercer, CJ | 1 |
| Hunt, D | 1 |
| Singer, H | 1 |
| Eschenbacher, HL | 1 |
| Gutheil, H | 1 |
| Toth, L | 1 |
| Velloso, LG | 1 |
| Santanna, AF | 1 |
| Barretto, AC | 1 |
| Lundström, T | 2 |
| Moor, E | 1 |
| Rydén, L | 2 |
| Denisiuk, VI | 3 |
| Lipnitskiĭ, TN | 3 |
| Kotsuta, GI | 2 |
| Pilipchuk, VP | 1 |
| Stepaniuk, AV | 2 |
| Osiadlaia, ES | 1 |
| Dobrotvorskaia, TE | 1 |
| Kazakevich, EV | 1 |
| Kuznetsova, LA | 1 |
| Kotlov, AP | 1 |
| Kolesnik, PF | 1 |
| Stoliarchuk, VA | 1 |
| Sizova, MP | 1 |
| Kubac, G | 1 |
| Malowany, L | 1 |
| Kingma, JH | 2 |
| Suttorp, MJ | 2 |
| Hohnloser, S | 1 |
| Müller, B | 1 |
| Tworek, DA | 1 |
| Nazari, J | 1 |
| Ezri, M | 1 |
| Bauman, JL | 1 |
| Inoue, M | 1 |
| Inoue, D | 1 |
| Omori, I | 1 |
| Shirayama, T | 1 |
| Yamahara, Y | 1 |
| Asayama, J | 1 |
| Katsume, H | 1 |
| Nakagawa, M | 1 |
| Gimrikh, EO | 1 |
| Chekhov, AM | 1 |
| Borisova, EV | 1 |
| Savenkova, GM | 1 |
| Plekhanov, IG | 1 |
| Matsuda, M | 1 |
| Matsuda, Y | 1 |
| Yamagishi, T | 1 |
| Takahashi, T | 1 |
| Haraguchi, M | 1 |
| Tada, T | 1 |
| Kusukawa, R | 1 |
| Christensen, C | 1 |
| Bell, A | 1 |
| Kondili, A | 1 |
| Kastrati, A | 1 |
| Popa, Y | 1 |
| Noc, M | 1 |
| Stajer, D | 1 |
| Horvat, M | 1 |
| Ometto, R | 1 |
| Arfiero, S | 1 |
| Vincenzi, M | 1 |
| Gonska, BD | 1 |
| Wiedey, KD | 1 |
| Craig, SA | 1 |
| Hudson, AD | 1 |
| Barnett, JC | 1 |
| Touchon, RC | 1 |
| Lewis, RV | 3 |
| McMurray, J | 1 |
| McDevitt, DG | 4 |
| Strasberg, B | 1 |
| Sagie, A | 1 |
| Rechavia, E | 1 |
| Katz, A | 1 |
| Ovsyscher, IA | 1 |
| Sclarovsky, S | 1 |
| Agmon, J | 1 |
| Lie-A-Huen, L | 1 |
| Mast, EG | 1 |
| Cordoni, M | 1 |
| Scalzini, A | 1 |
| Bechi, S | 1 |
| Franchini, C | 1 |
| Mazza, F | 1 |
| Micheli, G | 1 |
| Garratt, C | 2 |
| Antoniou, A | 1 |
| Camm, AJ | 2 |
| Platia, EV | 1 |
| Michelson, EL | 1 |
| Porterfield, JK | 1 |
| Das, G | 1 |
| Rabinowitz, H | 1 |
| Habot, B | 1 |
| Fridensohn, A | 1 |
| Schlesinger, Z | 1 |
| Ahuja, RC | 1 |
| Sinha, N | 1 |
| Saran, RK | 1 |
| Jain, AK | 1 |
| Hasan, M | 1 |
| James, MA | 2 |
| Channer, KS | 3 |
| Papouchado, M | 2 |
| Rees, JR | 2 |
| Vainer, J | 1 |
| Smíd, J | 1 |
| Cepeláková, H | 1 |
| Hapala, J | 1 |
| Topinka, I | 1 |
| Topolcan, O | 1 |
| Michel, B | 1 |
| Goy, JJ | 1 |
| Kappenberger, L | 1 |
| Sobrino, JA | 1 |
| Maté, I | 1 |
| Calvo, L | 1 |
| Plaza, I | 1 |
| Rico, J | 1 |
| Moreno, I | 1 |
| Mesa, JM | 1 |
| Ingerslev, J | 1 |
| Bangshøj, R | 1 |
| Jensen, E | 1 |
| Talley, JD | 1 |
| Wathen, MS | 1 |
| Hurst, JW | 1 |
| Bayés de Luna, A | 1 |
| Oter, MC | 1 |
| Aizawa, Y | 1 |
| Miyajima, S | 1 |
| Tamura, M | 1 |
| Shibata, A | 1 |
| Bump, TE | 1 |
| Ripley, KL | 1 |
| Guezennec, A | 1 |
| Arzbaecher, R | 1 |
| James, M | 1 |
| Tsialtas, D | 1 |
| Ghiringhelli, S | 1 |
| Cozzi, E | 1 |
| Glisenti, F | 1 |
| Straneo, U | 1 |
| Chittolini, L | 1 |
| Straneo, G | 1 |
| Dahlstrøm, CG | 2 |
| Ladefoged, SD | 2 |
| Hogg, KJ | 1 |
| Hornung, RS | 1 |
| Hillis, WS | 1 |
| Irvine, N | 1 |
| Pomfret, SM | 1 |
| Beasley, CR | 1 |
| Challenor, V | 1 |
| Holgate, ST | 1 |
| Falk, RH | 1 |
| Knowlton, AA | 1 |
| Manaker, S | 1 |
| Hricák, V | 1 |
| Kovácik, M | 1 |
| Shenasa, M | 1 |
| Kus, T | 1 |
| LeBlanc, RA | 1 |
| Dubuc, M | 1 |
| Nadeau, R | 1 |
| Belhassen, B | 1 |
| Viskin, S | 1 |
| Laniado, S | 1 |
| Mølgaard, H | 1 |
| Bjerregaard, P | 1 |
| Jørgensen, HS | 1 |
| Klitgaard, NA | 1 |
| Miura, D | 1 |
| Somberg, JC | 1 |
| Pitcher, DW | 1 |
| Lewis, R | 1 |
| Lakhani, M | 1 |
| Moreland, TA | 1 |
| Gautam, CS | 1 |
| Lal, R | 1 |
| Pandhi, P | 1 |
| Sharma, PL | 1 |
| Lewis, GB | 1 |
| Landau, E | 1 |
| Darawshi, A | 1 |
| Reisin, LH | 1 |
| McGovern, B | 1 |
| Garan, H | 1 |
| Ruskin, JN | 1 |
| Habbab, MA | 1 |
| Del Negro, AA | 1 |
| Fletcher, RD | 1 |
| Manoharan, S | 1 |
| Kaul, UA | 1 |
| Khalilullah, M | 1 |
| Ronderos, R | 1 |
| Escudero, EM | 1 |
| Winniford, MD | 1 |
| Hillis, LD | 1 |
| Ochs, HR | 1 |
| Anda, L | 1 |
| Greenblatt, DJ | 1 |
| Smith, EE | 1 |
| Shore, DF | 1 |
| Monro, JL | 1 |
| Ross, JK | 1 |
| Stafford, WJ | 1 |
| Bilsker, M | 1 |
| Zaman, L | 1 |
| Castellanos, A | 1 |
| Jacob, AS | 1 |
| Nielsen, DH | 1 |
| Gianelly, RE | 1 |
| Cummings, P | 1 |
| Laufer, N | 1 |
| Crevey, B | 1 |
| Bertrix, L | 1 |
| Timour Chah, Q | 1 |
| Lang, J | 1 |
| Lakhal, M | 1 |
| Bouzouita, K | 1 |
| Faucon, G | 1 |
| Doiuchi, J | 1 |
| Hamada, M | 1 |
| Ochi, T | 1 |
| Ito, T | 1 |
| Kokubu, T | 1 |
| Capella, G | 1 |
| Villani, R | 1 |
| Negro, R | 1 |
| Zolezzi, F | 1 |
| Veniani, M | 1 |
| Caprino, E | 1 |
| Baratto, T | 1 |
| Nava, S | 1 |
| Sotobata, I | 1 |
| Yamauchi, K | 1 |
| Tsuzuki, M | 1 |
| Noda, S | 1 |
| Hatano, K | 1 |
| Ito, E | 1 |
| Banasiak, W | 1 |
| Telichowski, C | 1 |
| Molenda, W | 1 |
| Kupczak, K | 1 |
| Hardewig, A | 1 |
| Diedrich, R | 1 |
| Antani, JA | 1 |
| Sriniwas, HV | 1 |
| Kock, R | 1 |
| Hartl, O | 1 |
| Clodi, PH | 1 |
| Chatillon, J | 1 |
| Loogen, F | 1 |
| Barousch, R | 1 |
| Chazov, EI | 1 |
| Doshchitsyn, VL | 1 |
| Arshakuni, RO | 1 |
| Zharov, EI | 1 |
| Gotsman, MS | 1 |
| Lewis, BS | 1 |
| Bakst, A | 1 |
| Mitha, AS | 1 |
| Heilmann, E | 1 |
| Bachour, G | 1 |
| Gradaus, D | 1 |
| Slome, R | 1 |
| Klempt, HW | 1 |
| Most, E | 1 |
| Schmidt, E | 1 |
| Kauschke, A | 1 |
| Spurrell, RA | 1 |
| Sowton, E | 1 |
| Garrett, C | 1 |
| Livesley, B | 2 |
| Oram, S | 2 |
| Filias, N | 1 |
| Zanoni, G | 1 |
| Vaughan-Neil, EF | 1 |
| Snell, NJ | 1 |
| Bevan, G | 1 |
| De Soldati, L | 1 |
| Stritzler, G | 1 |
| Balassanian, S | 1 |
| Fuksman, A | 1 |
| Mario Krasnov, C | 1 |
| Rosental, R | 1 |
| Chutlian, A | 1 |
| Fabregas, R | 1 |
| Catley, PF | 1 |
| Kidner, PH | 1 |
| Bass, O | 1 |
| Friedemann, M | 1 |
| Garvey, HL | 1 |
| Betz, GG | 1 |
| Olesch, K | 1 |
| Schmidt-Voigt, J | 1 |
| Kojima, N | 1 |
| Reploh, HD | 1 |
| Oelmann, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| Rate Control in Atrial Fibrillation II[NCT02695992] | Phase 4 | 122 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Rate Control in Atrial Fibrillation[NCT00313157] | Phase 3 | 80 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy[NCT04133532] | Phase 4 | 22 participants (Actual) | Interventional | 2020-03-05 | Completed | ||
| Correlation Between Myocardial Deformation and Coronary Artery Morphology in Patients With Hypertrophic Cardiomyopathy and Analysis of Genetic Factors：A Prospective, Single-center, Case-control Study[NCT04830787] | 302 participants (Actual) | Observational | 2017-12-01 | Completed | |||
| Reveal® XT Performance Trial[NCT00680927] | Phase 4 | 247 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias[NCT03413150] | 80 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms[NCT02758002] | 0 participants (Actual) | Interventional | 2016-01-28 | Withdrawn | |||
| Randomized Clinical Trial to Study Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation by Vernakalant and Flecainide[NCT03005366] | Phase 4 | 50 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| Comparism Between Efficacy and Effectiveness Between Slow Infusion of Calcium Channel Blockers and Intravenous Bolus Adenosine in the Management of Supraventricular Tachycardia in the Emergency Department.[NCT00413712] | Phase 4 | 206 participants | Interventional | 1997-01-31 | Completed | ||
| Calcium Administration to Prevent Hypotension Caused by Diltiazem Administration in the Treatment of Atrial Fibrillation With Rapid Ventricular Response[NCT05691959] | Phase 2 | 378 participants (Anticipated) | Interventional | 2023-01-26 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
51 reviews available for verapamil and Auricular Fibrillation
| Article | Year |
|---|---|
Bayesian Network Meta-analysis of Randomized Controlled Trials on the Efficacy of Antiarrhythmics in the Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Flecainide; H | 2023 |
[The atrial electrical remodeling in atrial fibrillation].
Topics: Animals; Atrial Fibrillation; Calcium; Calcium Channel Blockers; Electrophysiology; Heart Atria; Hum | 2002 |
Acute atrial fibrillation.
Topics: Acute Disease; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Electrocardiography; | 2002 |
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Pacing, Artificial; | 2003 |
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Pacing, Artificial; | 2003 |
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Pacing, Artificial; | 2003 |
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Pacing, Artificial; | 2003 |
Atrial stunning: basics and clinical considerations.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Function; Atrial Functi | 2003 |
Facilitating electrical cardioversion of persistant atrial fibrillation by antiarrhythmic drugs: update on clinical trial results.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans; Propafenone; Randomized | 2003 |
Pharmacological rate control of atrial fibrillation.
Topics: Amiodarone; Atenolol; Atrial Fibrillation; Cardiotonic Agents; Digoxin; Diltiazem; Heart Rate; Human | 2004 |
Atrial fibrillation (acute).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Humans; Timolol; Verapa | 2003 |
Acute management of atrial fibrillation: the commonest arrhythmia in clinical practice.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Protocols; Electric Countershock; Electrocardi | 2004 |
Atrial fibrillation (acute).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Flecainide; Humans; Pro | 2003 |
Atrial fibrillation (acute).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Flecainide; Humans; Pro | 2004 |
Atrial fibrillation (recent onset).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Flecainide; Humans; Pro | 2005 |
Pharmacologic therapy of tachyarrhythmias in patients with Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Ajmaline; Amiodarone; Anilides; Aprindine; Atr | 1983 |
Verapamil/beta-blocker interaction. A review.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Atrial Flutter; Calcium; Drug Interactions; | 1983 |
The treatment of atrial fibrillation and flutter: a review.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Ar | 1984 |
Calcium antagonists and their potential role in the prevention of sudden coronary death.
Topics: Action Potentials; Animals; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Calcium Chan | 1982 |
Management of arrhythmias with "calcium antagonists".
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Calcium; Calcium C | 1982 |
Calcium antagonists. Clinical use in the treatment of arrhythmias.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Calcium Channel Blockers; Death, | 1983 |
[Discrepant effects of oral and intravenous verapamil on A-V conduction in patients with ventricular preexcitation and atrial fibrillation].
Topics: Administration, Oral; Adolescent; Adult; Aged; Atrial Fibrillation; Atrioventricular Node; Bundle of | 1983 |
Antiarrhythmic effects of verapamil.
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; At | 1983 |
Verapamil in cardiac arrhythmias: an overview.
Topics: Administration, Oral; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Calcium Channel Blo | 1982 |
Verapamil and digoxin: their respective effects on atrial fibrillation and their interaction.
Topics: Action Potentials; Administration, Oral; Atrial Fibrillation; Atrioventricular Node; Autonomic Nervo | 1982 |
The clinical use of intravenous verapamil.
Topics: Angina Pectoris, Variant; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Atrioventricula | 1980 |
Management of rapid ventricular rate in acute atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Heart Rate; Humans; Propranolol; Ve | 1994 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Fle | 1993 |
Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Aspirin; Atrial Fibri | 1996 |
[Control of heart rate and atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Chronic Disease; Digitalis Glycosides; Diltiazem; | 1996 |
The management of hypertrophic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cardiac Pacing, Artificial; Cardiomyopathy, Hypert | 1997 |
[Verapamil and diltiazem in the treatment of atrial fibrillation].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Contraindications; Diltiazem; Humans; Verapamil | 1997 |
Atrial fibrillation: what are the effects of drug therapy on the effectiveness and complications of electrical cardioversion?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Digoxin; Electri | 1998 |
The evidence regarding the drugs used for ventricular rate control.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Bias; Calcium Chann | 2000 |
Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cost-Benefit An | 2000 |
Supraventricular tachycardia: implications for the intensivist.
Topics: Adenosine; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiogra | 2000 |
Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Atrial Fibrillation; Bradycardia; Calcium Channel Block | 2000 |
Pharmacologic management of atrial fibrillation: current therapeutic strategies.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; | 2001 |
Tachycardia induced changes of atrial electrophysiological properties.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Electrophysiology; | 2000 |
Update on atrial remodelling owing to rate; does atrial fibrillation always 'beget' atrial fibrillation?
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Electrophysiologic T | 2001 |
[Mechanisms of initiation in atrial fibrillation].
Topics: Action Potentials; Algorithms; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel | 2002 |
Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Appendage; Atrial Fibrillation; Atrial | 2002 |
Clinical use of verapamil.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Atrial Fibrillation; Heart Conduction System; Hemodynamics; H | 1977 |
Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil.
Topics: Action Potentials; Administration, Oral; Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial | 1975 |
Interference by antiarrhythmic agents with function of electrical cardiac devices.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, Cardiac; Digoxin; Drug Interactions; Ele | 1992 |
[Interaction between calcium antagonists and digoxin].
Topics: Atrial Fibrillation; Calcium Channel Blockers; Digoxin; Diltiazem; Drug Interactions; Humans; Nifedi | 1991 |
Management of supraventricular tachyarrhythmias.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia; Huma | 1989 |
Pharmacokinetics of calcium channel blocking agents.
Topics: Administration, Oral; Angina Pectoris; Atrial Fibrillation; Biological Availability; Cardiomegaly; C | 1986 |
Digitalis and verapamil in atrial fibrillation and flutter. Is verapamil now the preferred agent?
Topics: Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Digitalis Glycosides; Drug Therapy, Comb | 1986 |
Supraventricular tachyarrhythmias: their evaluation and therapy.
Topics: Acute Disease; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Calcium Channel Blockers | 1986 |
Calcium antagonists in patients with cardiovascular disease. Current perspectives.
Topics: Angina Pectoris; Angina Pectoris, Variant; Atrial Fibrillation; Atrial Flutter; Benzazepines; Cardio | 1985 |
[Heart rhythm disorders during pacemaker therapy].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Complexes, Premature; Electricity | 1973 |
[Anti-arrhythmia agents].
Topics: Action Potentials; Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atri | 1974 |
[Treatment of arrhythmia in myocardial infarct].
Topics: Amides; Arrhythmias, Cardiac; Atrial Fibrillation; Atropine; Cardiac Complexes, Premature; Cardiac G | 1968 |
85 trials available for verapamil and Auricular Fibrillation
| Article | Year |
|---|---|
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Calcium Channel Blockers; Diltiazem | 2017 |
Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Calcium Channel Blockers; Carbazoles; Carved | 2014 |
Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Calcium Channel Blockers; Carbazoles; Carved | 2014 |
Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Calcium Channel Blockers; Carbazoles; Carved | 2014 |
Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Calcium Channel Blockers; Carbazoles; Carved | 2014 |
Improved rate control reduces cardiac troponin T levels in permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Carbazoles; Carved | 2014 |
Improved rate control reduces cardiac troponin T levels in permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Carbazoles; Carved | 2014 |
Improved rate control reduces cardiac troponin T levels in permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Carbazoles; Carved | 2014 |
Improved rate control reduces cardiac troponin T levels in permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Carbazoles; Carved | 2014 |
Rate-control drugs affect variability and irregularity measures of RR intervals in patients with permanent atrial fibrillation.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr | 2015 |
Troponin I levels in permanent atrial fibrillation-impact of rate control and exercise testing.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; B | 2016 |
Comparison of verapamil and ibutilide for the suppression of immediate recurrences of atrial fibrillation after transthoracic cardioversion.
Topics: Aged; Atrial Fibrillation; Chi-Square Distribution; Electric Countershock; Female; Follow-Up Studies | 2002 |
Effects of verapamil and metoprolol on recovery from atrial electrical remodeling after cardioversion of long-lasting atrial fibrillation.
Topics: Aged; Analysis of Variance; Atrial Fibrillation; Atrial Function; Calcium Channel Blockers; Echocard | 2003 |
Rate-dependent effect of verapamil on atrial refractoriness.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channels; Electrophysiologic Techniques, | 2003 |
[Verapamil in the cardioversion of atrial fibrillation. Clinical study].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Humans; Male; Refr | 2003 |
VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2003 |
Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Electric Countersh | 2004 |
Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blin | 2004 |
A controlled study on the effect of verapamil on atrial tachycaarrhythmias in patients with brady-tachy syndrome implanted with a DDDR pacemaker.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiac Pacing, A | 2005 |
Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cross-Over Studies; Electric Counters | 2005 |
Rate control and quality of life in patients with permanent atrial fibrillation: the Quality of Life and Atrial Fibrillation (QOLAF) Study.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cross-Over Studies; | 2006 |
Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium; Digoxin; Electric Countershock; Female; | 2006 |
Event-recorder monitoring in the diagnosis of atrial fibrillation in symptomatic patients: subanalysis of the SOPAT trial.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Electrocardiography, Ambulatory; H | 2006 |
Signal-averaged P wave reflects change in atrial electrophysiological substrate afforded by verapamil following cardioversion from atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Electric Countershock; | 2006 |
Effect of oral L-type calcium channel blocker on repetitive paroxysmal atrial fibrillation: spectral analysis of fibrillation waves in the Holter monitoring.
Topics: Adult; Aged; Atrial Fibrillation; Calcium Channel Blockers; Disease Progression; Electrocardiography | 2007 |
Comparison of rate and rhythm control in hypertension patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2008 |
Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Clinical Trials as Topic; Digoxin; Drug Ther | 1983 |
Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Clinical Tr | 1983 |
[Modification of hemodynamics in tachycardiac atrial fibrillation by metoprolol and verapamil].
Topics: Atrial Fibrillation; Cardiac Output; Cardiomyopathy, Dilated; Heart Rate; Hemodynamics; Humans; Meto | 1983 |
Atrial fibrillation and flutter. Immediate control and conversion with intravenously administered verapamil.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Double-Blind Method; Drug Evaluati | 1983 |
Double-blind crossover randomized trial of intravenously administered verapamil. Its use for atrial fibrillation and flutter following open heart surgery.
Topics: Adult; Aged; Atrial Fibrillation; Blood Pressure; Double-Blind Method; Drug Evaluation; Electrophysi | 1984 |
Verapamil improves exercise capacity in chronic atrial fibrillation: double-blind crossover study.
Topics: Adult; Aged; Atrial Fibrillation; Blood Pressure; Digoxin; Double-Blind Method; Exercise Test; Femal | 1983 |
Verapamil versus placebo in atrial fibrillation and atrial flutter.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Dose-Response Relationsh | 1980 |
Treatment of paroxysmal supraventricular tachycardia and atrial flutter-fibrillation with intravenous verapamil: efficacy and mechanism of action.
Topics: Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Double-Blind Method; Electrocardiogra | 1980 |
Pharmacodynamic comparison of oral and intravenous verapamil in atrial fibrillation.
Topics: Administration, Oral; Adult; Atrial Fibrillation; Biological Availability; Clinical Trials as Topic; | 1980 |
Comparative efficiency of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation. A controlled clinical trial.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Clinical Trials as Topic; Electric Stimulation Therapy; H | 1981 |
Treatment of supraventricular arrhythmias with intravenous and oral verapamil.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Blood Pressure; Clinical Trials as Topic; Do | 1981 |
Verapamil therapy of atrial fibrillation and atrial flutter following cardiac operation.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Cardiac Surgical Procedures; Clini | 1982 |
Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Blood Pressure; Chronic Disease; Double-Blin | 1982 |
Treatment of chronic atrial fibrillation in the elderly, assessed by ambulatory electrocardiographic monitoring.
Topics: Aged; Atrial Fibrillation; Digoxin; Drug Tolerance; Electrocardiography; Evaluation Studies as Topic | 1980 |
Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Dose-Response Relationship, Drug; Double-Blind Met | 1981 |
[Amiodarone and verapamil/quinidine in treatment of patients with chronic atrial fibrillation].
Topics: Aged; Amiodarone; Atrial Fibrillation; Chronic Disease; Dose-Response Relationship, Drug; Drug Admin | 1994 |
[Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation--conversion and 12-month follow-up--a randomized comparison].
Topics: Aged; Atrial Fibrillation; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Adminis | 1994 |
Clinical course of recent-onset atrial fibrillation treated with oral propafenone.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Heart Rate; Humans; Middle Aged; Propafenone; Verap | 1994 |
Amiodarone and the development of ARDS after lung surgery.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Humans; Incidence; Middle Aged; Pneumonectomy; Postope | 1994 |
The effect of magnesium versus verapamil on supraventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Female; Heart Rate; Humans; Infusions, In | 1993 |
[Urban & Vogel Workshop. Atrial fibrillation--decision aids for ambulatory therapy].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Double-Blind Me | 1995 |
Verapamil as prophylactic treatment for atrial fibrillation after lung operations.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Humans; Hypotension; Incidence | 1996 |
Efficacy of intravenous magnesium sulphate in supraventricular tachyarrhythmias.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Female; Heart Ra | 1995 |
Effectiveness of verapamil-quinidine versus digoxin-quinidine in the emergency department treatment of paroxysmal atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Double-Blind Method; Drug Therapy | 1997 |
Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Electroph | 1998 |
Modulation of ventricular rate in permanent atrial fibrillation: randomized, crossover study of the effects of slow-release formulations of gallopamil, diltiazem, or verapamil.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; C | 1998 |
[Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT Study. Executive committee of the investigators representing trial physicians].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dose-Response Relationship, Drug; Doubl | 1999 |
[Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Dis | 1999 |
Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Combined Modality Therapy; Elect | 1999 |
Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Premature Comple | 1999 |
Left atrial and appendage mechanical function after pharmacological or electrical cardioversion in patients with chronic atrial fibrillation: a multicenter, randomized study.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Appendage; Atrial Fibrillation; Atrial Function, Left; Blood Fl | 2000 |
Effect of verapamil on immediate recurrence of atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Calcium Channel Blockers; Electric Countershock; Female; Heart Rate; Huma | 2000 |
Effects of pretreatment with verapamil on early recurrences after electrical cardioversion of persistent atrial fibrillation: a randomised study.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Electric Countershock; | 2001 |
Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing.
Topics: Administration, Oral; Aged; Area Under Curve; Atrial Fibrillation; Blood Pressure; Calcium Channel B | 2001 |
Effect of verapamil on prevention of atrial fibrillation in patients implanted with an implantable atrial defibrillator.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Cross-Over Studies; Defibrill | 2001 |
VERDICT: the Verapamil versus Digoxin Cardioversion Trial: A randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium; Calcium Channel Blockers; Digoxin; Elect | 2001 |
Clinical assessment of clonidine in the treatment of new-onset rapid atrial fibrillation: a prospective, randomized clinical trial.
Topics: Acute Disease; Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressu | 2001 |
Effect of verapamil on secondary cardioversion in patients with early atrial fibrillation recurrence after electrical cardioversion.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Electr | 2002 |
[Verapamil as an anti-arrhythmic agent. Experience with 86 consecutive cases treated by intravenous injection].
Topics: Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Clinical Trials as Topic; Drug Evaluation; Heart Ar | 1977 |
Effect of oral verapamil on ventricular irregularity in long-standing atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Blood Pressure; Chronic Disease; Clinical Tr | 1979 |
Verapamil in atrial fibrillation and atrial flutter.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Electrocardiography; Humans; Male; Middle Ag | 1979 |
Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation.
Topics: Adrenergic beta-Agonists; Aged; Atrial Fibrillation; Chronic Disease; Double-Blind Method; Electroca | 1992 |
Functional capacity of patients with atrial fibrillation and controlled heart rate before and after cardioversion.
Topics: Aged; Atrial Fibrillation; Chronic Disease; Clinical Protocols; Electric Countershock; Exercise Test | 1992 |
[Prospective course of therapy arresting attacks of atrial fibrillation in patients with preexcitation syndromes].
Topics: Adult; Aged; Aged, 80 and over; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; D | 1992 |
Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil.
Topics: Atrial Fibrillation; Atrial Flutter; Drug Evaluation; Female; Flecainide; Humans; Male; Middle Aged; | 1992 |
Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up.
Topics: Amiodarone; Atrial Fibrillation; Chronic Disease; Drug Therapy, Combination; Electrocardiography; Fe | 1992 |
[Evaluation of the possibility of selection of individual anti-arrhythmia therapy].
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Humans; Middle Aged; P | 1991 |
Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm.
Topics: Adult; Aged; Atrial Fibrillation; Electrocardiography; Female; Flecainide; Heart Rate; Humans; Infus | 1990 |
Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm.
Topics: Aged; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Male; Randomized Control | 1990 |
[Delayed-release verapamil hydrochloride in chronic atrial fibrillation. Reducing the heart rate].
Topics: Aged; Atrial Fibrillation; Delayed-Action Preparations; Female; Heart Rate; Humans; Male; Middle Age | 1990 |
Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil.
Topics: Aged; Anaerobic Threshold; Atrial Fibrillation; Diltiazem; Electrocardiography, Ambulatory; Female; | 1990 |
Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.
Topics: Adrenergic beta-Agonists; Aged; Atenolol; Atrial Fibrillation; Chronic Disease; Digitalis Glycosides | 1989 |
Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Female; Flecainide; Hear | 1989 |
Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Clini | 1989 |
Digoxin or verapamil or metoprolol for heart rate control in patients with mitral stenosis--a randomised cross-over study.
Topics: Adult; Arrhythmia, Sinus; Atrial Fibrillation; Digoxin; Heart Rate; Humans; Metoprolol; Mitral Valve | 1989 |
Improved control of atrial fibrillation with combined pindolol and digoxin therapy.
Topics: Adult; Aged; Atrial Fibrillation; Digoxin; Drug Therapy, Combination; Dyspnea; Female; Heart Rate; H | 1989 |
Interatrial conduction block with retrograde activation of the left atrium and paroxysmal supraventricular tachyarrhythmias: influence of preventive antiarrhythmic treatment.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiography; | 1989 |
Pharmacokinetics of calcium channel blocking agents.
Topics: Administration, Oral; Angina Pectoris; Atrial Fibrillation; Biological Availability; Cardiomegaly; C | 1986 |
Factors affecting the clinical response to treatment with digoxin and two calcium antagonists in patients with atrial fibrillation.
Topics: Atrial Fibrillation; Calcium Channel Blockers; Clinical Trials as Topic; Digoxin; Diltiazem; Double- | 1988 |
Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem.
Topics: Aged; Atrial Fibrillation; Cardiac Output; Chronic Disease; Digoxin; Diltiazem; Heart Rate; Humans; | 1988 |
Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Chronic Disease; Clinical Trials as Topic; Digoxin; Double-Blind Method; | 1988 |
Towards improved control of atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Chronic Disease; Circadian Rhythm; Clinical Trials as Topic; Digoxin; Dos | 1987 |
A comparison of verapamil and digoxin in the treatment of atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Chronic Disease; Clinical Trials as Topic; Digoxin; Dose-Response Relatio | 1987 |
Diltiazem, verapamil, and quinidine in patients with chronic atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Benzazepines; Chronic Disease; Clinical Trials as Topic | 1985 |
Oral verapamil fails to prevent supraventricular tachycardia following coronary artery surgery.
Topics: Administration, Oral; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Coronary Artery | 1985 |
242 other studies available for verapamil and Auricular Fibrillation
| Article | Year |
|---|---|
Is there a role for verapamil beyond rate control in paroxysmal atrial fibrillation?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Tachycardia, Paroxysmal; Verapamil | 2022 |
Clinically Significant Bradycardia and Hypotension Following Consumption of Betel Leaf in a Patient Treated for Chronic Atrial Fibrillation.
Topics: Aged; Atrial Fibrillation; Bradycardia; Diabetes Mellitus, Type 2; Female; Humans; Hypotension; Meto | 2023 |
Comments of the editorial board on the article "The incidence of atrial infarction in patients with supraventricular arrhythmias" (authors: Bocharov A.V., Popov L.V. DOI:10.18087/cardio.2022.3.n1648).
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Heart Atria; Humans; Incidence; Infarction; Verapamil | 2022 |
Association between hemorrhage and direct oral anticoagulants in combination with verapamil: Analysis of Japanese Adverse Drug Event Report database and electronic medical record data.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Anticoagulants; Atrial Fibrillation; | 2023 |
Association of Nondihydropyridine Calcium Channel Blockers Versus β-Adrenergic Receptor Blockers With Risk of Heart Failure Hospitalization.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Calcium Channel Blockers; Diltiazem; Heart F | 2023 |
Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Computer Simulation; D | 2019 |
Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Databases, Factua | 2020 |
Comparative Efficacy and Safety of Intravenous Verapamil and Diltiazem for Rate Control in Rapidly Conducted Atrial Fibrillation and Atrial Flutter.
Topics: Administration, Intravenous; Atrial Fibrillation; Atrial Flutter; Diltiazem; Humans; Verapamil | 2020 |
Bradycardia Shock Caused by the Combined Use of Carteolol Eye Drops and Verapamil in an Elderly Patient with Atrial Fibrillation and Chronic Kidney Disease.
Topics: Aged; Atrial Fibrillation; Bradycardia; Carteolol; Humans; Japan; Ophthalmic Solutions; Renal Insuff | 2021 |
Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation.
Topics: Aged, 80 and over; Amlodipine; Atrial Fibrillation; Calcium Channel Blockers; Cross-Sectional Studie | 2020 |
Hypermagnesuria in Humans Following Acute Intravenous Administration of Digoxin.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; D | 2018 |
Identification of Verapamil Binding Sites Within Human Kv1.5 Channel Using Mutagenesis and Docking Simulation.
Topics: Amino Acid Substitution; Animals; Atrial Fibrillation; Binding Sites; CHO Cells; Cricetulus; Humans; | 2019 |
Treatment with verapamil for restoration of sinus rhythm in atrial fibrillation with rapid ventricular response: A case report.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Female; Hum | 2019 |
Acute effects of simvastatin to terminate fast reentrant tachycardia through increasing wavelength of atrioventricular nodal reentrant tachycardia circuit.
Topics: Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular Node; Brugada Syndrome; Cardiac | 2015 |
[Cardiogenic shock after drug therapy for atrial fibrillation with tachycardia : Case report of an 89-year-old woman].
Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Critical Care; Drug Interactions; Dr | 2016 |
[Drug treatment for hypertrophic cardiomyopathy].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiomyop | 2009 |
Is verapamil a double-edged sword in rate control of paroxysmal atrial fibrillation?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Heart Atria; Heart Rate; Humans; | 2010 |
Verapamil eliminates the hierarchical nature of activation frequencies from the pulmonary veins to the atria during paroxysmal atrial fibrillation.
Topics: Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Coronary Sinus | 2010 |
Role of the atrial rate as a factor modulating ventricular response during atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography, | 2010 |
Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8).
Topics: Acetanilides; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Autistic Disorder; Drug Therapy, C | 2012 |
Coexistent idiopathic left ventricular tachycardia and atrial fibrillation induced by maintained VA conduction during ventricular tachycardia.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Echocardiography; Electrocard | 2012 |
[The choked heart].
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Calcium Channel Blockers; Cardia | 2012 |
Vasospastic angina with J-wave pattern and polymorphic ventricular tachycardia effectively treated with quinidine.
Topics: Angina Pectoris, Variant; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Combined Modality | 2012 |
Digoxin-associated decrease in parathyroid hormone (PTH) concentrations in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium; Digoxin; Female; Fibr | 2013 |
Epidemiology of atrial fibrillation.
Topics: Atrial Fibrillation; Digoxin; Humans; United Kingdom; Verapamil | 2002 |
Sudden death due to atrial fibrillation in hypertrophic cardiomyopathy: a predictable event in a young patient.
Topics: Adult; Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Defibr | 2003 |
[Effects of verapamil on atrial fibrillation spontaneous initiation in the intact canine heart].
Topics: Animals; Atrial Fibrillation; Calcium Channel Blockers; Cholinergic Fibers; Dogs; Heart Atria; Verap | 2003 |
[Effect of calcium antagonists verapamil and amlodipine on the risk of development of atrial fibrillation after coronary artery bypass grafting].
Topics: Adult; Aged; Amlodipine; Atrial Fibrillation; Calcium Channel Blockers; Coronary Artery Bypass; Huma | 2003 |
Impact of left atrial size reduction on chronic atrial fibrillation in mitral valve surgery.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pac | 2003 |
Verapamil suppresses the inhomogeneity of electrical remodeling in a canine long-term rapid atrial stimulation model.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artifici | 2003 |
Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antimetabolites, Antineoplas | 2003 |
[Correction of rate and structure of ventricular rhythm in permanent atrial fibrillation: a novel pathogenetic approach].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Digoxin; Electrocardi | 2004 |
Cardioversion threshold, IRAF and beyond.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Flecainide; Humans; | 2004 |
A comparison between calcium channel blocking drugs with different potencies for T- and L-type channels in preventing atrial electrical remodeling.
Topics: Administration, Oral; Animals; Atrial Fibrillation; Atrioventricular Node; Calcium; Calcium Channel | 2004 |
[Stroke and other thromboembolic complications of atrial fibrillation. Part v. The use of drugs without antithrombotic or antiarrhythmic properties.].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans; Stroke; Verapamil | 2004 |
Response to pharmacological challenge of dissociated pulmonary vein rhythm.
Topics: Adenosine; Atrial Fibrillation; Female; Humans; Isoproterenol; Male; Middle Aged; Phenylephrine; Pul | 2005 |
Quinidine plus verapamil vs. quinidine alone to prevent recurrences of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Humans; Quinidine; Secondary | 2005 |
[PAFAC Study. Secondary prevention of atrial fibrillation after cardioversion].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therap | 2005 |
Ectopic activity induced by elevated atrial pressure in rabbit pulmonary vein in vitro.
Topics: Action Potentials; Animals; Atrial Fibrillation; Atrial Function, Left; Cardiac Pacing, Artificial; | 2005 |
Modified release verapamil induced cardiogenic shock.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Delayed-Action Preparations; Humans; Male; Middle Aged; | 2005 |
Discordant repolarization alternans-induced atrial fibrillation is suppressed by verapamil.
Topics: Action Potentials; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; E | 2005 |
Deglutition-induced atrial fibrillation.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Deglutition; Disopyramide; Drug Therapy, Combina | 2005 |
Inadvertent toxic drug reaction in the management of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Digoxin; Drug Interactions; Electrocardiog | 2006 |
Hypertrophic cardiomyopathy. Combination of beta blockers and verapamil may be risky.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Hypertroph | 2006 |
A case of a borderline-broad complex tachycardia.
Topics: Adenosine; Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle-Branch Block; Carotid Sinus; Diagnosi | 2006 |
Calcium-mediated triggered activity is an underlying cellular mechanism of ectopy originating from the pulmonary vein in dogs.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Autonomic Nervous System; C | 2007 |
A new role for extracellular Ca2+ in gap-junction remodeling: studies in humans and rats.
Topics: Animals; Atrial Fibrillation; Calcium; Cells, Cultured; Connexin 43; Connexins; Cyclosporine; Female | 2008 |
[Treatment of supraventricular tachycardia].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter | 1981 |
[Effects of anti-arrhythmia agents on heart rate. Significance and importance].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 1981 |
[Pharmacotherapy of paroxysmal tachycardia].
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Atrial Flutter; Digitalis Glycosides; Disopyramide | 1983 |
[Conservative therapy of supraventricular tachycardias].
Topics: Adrenergic beta-Antagonists; Ajmaline; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; | 1984 |
[Combination treatment of atrial arrhythmias with quinidine-verapamil].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Complexes, Premature; | 1980 |
[Enhancement of the antifibrillatory efficacy of quinidine in atrial fibrillation by verapamil (author's transl)].
Topics: Animals; Atrial Fibrillation; Cardiac Complexes, Premature; Cardiac Pacing, Artificial; Diltiazem; D | 1982 |
Electropharmacology of the slow-channel inhibitors in the management of cardiac arrhythmias: verapamil.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Heart Conduction Sys | 1982 |
[Chinidin and verapamil combined against atrial arrhythmias].
Topics: Atrial Fibrillation; Atrial Flutter; Cardiac Complexes, Premature; Drug Therapy, Combination; Heart | 1982 |
Atrial fibrillation.
Topics: Age Factors; Aged; Atrial Fibrillation; Cardiomegaly; Digoxin; Electric Countershock; Electrocardiog | 1982 |
The use of encainide in atrial fibrillation.
Topics: Anilides; Anti-Arrhythmia Agents; Atrial Fibrillation; Encainide; Humans; Male; Verapamil | 1984 |
Advances in the management of cardiac arrhythmias in children.
Topics: Adolescent; Adult; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Pa | 1984 |
Verapamil in chronic atrial fibrillation: variable patterns of response in ventricular rate.
Topics: Adult; Aged; Atrial Fibrillation; Electrocardiography; Female; Heart Rate; Humans; Kinetics; Male; M | 1984 |
Verapamil: a cause of sudden death in a patient with hypertrophic cardiomyopathy.
Topics: Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden; Electrocardiography; Heart Block; | 1984 |
Decreased serum lithium during verapamil therapy.
Topics: Aged; Atrial Fibrillation; Bipolar Disorder; Cardiomyopathy, Hypertrophic; Female; Humans; Lithium; | 1984 |
The "holiday heart" syndrome.
Topics: Alcohol Drinking; Atrial Fibrillation; Electrocardiography; Ethanol; Humans; Male; Middle Aged; Vera | 1984 |
Electrophysiological effects of quinidine alone and of the combination quinidine-verapamil on AV conduction in humans.
Topics: Adult; Arrhythmias, Cardiac; Atrial Fibrillation; Bundle of His; Bundle-Branch Block; Drug Therapy, | 1983 |
Verapamil therapy in the treatment of supraventricular arrhythmias following open heart surgery.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Cardiac Surgi | 1983 |
Long-term oral treatment with high doses of verapamil in lone atrial fibrillation.
Topics: Administration, Oral; Adult; Atrial Fibrillation; Digoxin; Drug Interactions; Heart Rate; Humans; Ma | 1984 |
[Regularization of ventricular intervals in atrial fibrillation--electrophysiologic findings on the underlying mechanism].
Topics: Adult; Aged; Atrial Fibrillation; Atrioventricular Node; Cardiac Pacing, Artificial; Electrocardiogr | 1984 |
[Treatment of paroxysmal supraventricular tachycardia and tachyarrhythmia with verapamil].
Topics: Adult; Aged; Atrial Fibrillation; Blood Pressure; Drug Evaluation; Female; Heart Rate; Humans; Male; | 1984 |
Calcium and calciferol antagonise effect of verapamil in atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Calcium; Ergocalciferols; Humans; Male; Verapamil | 1981 |
Safety and efficacy of short- and long-term verapamil therapy in children with tachycardia.
Topics: Administration, Oral; Atrial Fibrillation; Child; Child, Preschool; Dose-Response Relationship, Drug | 1981 |
[Combined administration of quinidine and verapamil in chronic atrial fibrillation and atrial flutter (author's transl].
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Drug Combinations; Female; Humans; Male; Middle Ag | 1982 |
Electroversion after verapamil administration.
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Atrial Flutter; Electric Countershock; Female; Humans; | 1983 |
Electrophysiologic evaluation of antiarrhythmic drugs on supraventricular tachyarrhythmias.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Disopyramide; El | 1983 |
Intravenous verapamil to relieve pulmonary congestion in patients with mitral valve disease.
Topics: Aged; Atrial Fibrillation; Female; Heart Failure; Humans; Injections, Intravenous; Middle Aged; Mitr | 1983 |
[Treatment of paroxysmal forms of auricular fibrillation and atrial flutter in a cardiological hospital].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Glycosides; Drug T | 1983 |
Supraventricular tachycardias.
Topics: Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Diagnosis, Differential; Electric Counte | 1983 |
Augmented ventricular rate following verapamil treatment for atrial fibrillation with Wolff-Parkinson-White syndrome.
Topics: Atrial Fibrillation; Child; Electrocardiography; Female; Heart Conduction System; Heart Ventricles; | 1983 |
Verapamil in atrial fibrillation: The expected, the unexpected, and the unknown.
Topics: Atrial Fibrillation; Digoxin; Drug Interactions; Heart Ventricles; Humans; Kinetics; Verapamil; Wolf | 1983 |
Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil.
Topics: Adult; Aged; Atrial Fibrillation; Female; Heart Conduction System; Heart Rate; Humans; Male; Refract | 1982 |
Intravenous Calcium chloride as an antidote to verapamil-induced hypotension.
Topics: Aged; Atrial Fibrillation; Binding, Competitive; Calcium Chloride; Humans; Hypotension; Male; Verapa | 1982 |
The influence of verapamil on serum digoxin concentration.
Topics: Adult; Aged; Atrial Fibrillation; Chronic Disease; Digoxin; Dose-Response Relationship, Drug; Drug I | 1982 |
Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation.
Topics: Administration, Oral; Atrial Fibrillation; Blood Pressure; Chronic Disease; Digoxin; Dose-Response R | 1982 |
The five fingers of cardiology.
Topics: Atrial Fibrillation; Electrocardiography; Female; Humans; Middle Aged; Verapamil | 1982 |
Prolongation of verapamil elimination kinetics during chronic oral administration.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Chromatography, High Pressure Liquid; Female; Half- | 1982 |
Rapid atrial fibrillation during hypercalcemia despite verapamil therapy.
Topics: Aged; Atrial Fibrillation; Calcium; Female; Humans; Hypercalcemia; Male; Middle Aged; Verapamil | 1982 |
[Heart rate reduction in atrial fibrillation with a rapid ventricular response by Gallopamil, a Ca-antagonist (author's transl)].
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Atrioventricular Node; Calcium Channel Block | 1982 |
Clinical pharmacokinetics of verapamil in patients with atrial fibrillation.
Topics: Administration, Oral; Atrial Fibrillation; Biological Availability; Female; Heart Rate; Humans; Inje | 1982 |
Unusual response to intravenous verapamil in a patient with atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Electrocardiography; Heart Ventricles; Humans; Infusions, Parenteral; Mal | 1982 |
Effects of verapamil on the electrophysiologic properties of the accessory pathway in patients with the Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Cardiac Pacing, Artificial; Electrocardiography; Female; Heart Conductio | 1982 |
Verapamil disposition kinetics in chronic atrial fibrillation.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Chronic Disease; Female; Humans; Infusions, Parente | 1981 |
[Quinidine and verapamil combination therapy for the treatment of atrial arrhythmias].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Drug Combinations; Heart Atria; Humans; Quinidine; Verapa | 1981 |
[Conversion of recent atrial fibrillation to sinus rhythm. Predictive value of the clinical and echocardiographic parameters].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Digitalis Glycosides; Echocardiography; E | 1981 |
Verapamil and supraventricular tachyarrhythmias: beneficial effect in patients with chronic pulmonary disease.
Topics: Aged; Atrial Fibrillation; Atrial Flutter; Blood Gas Analysis; Chronic Disease; Electrocardiography; | 1980 |
Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias.
Topics: Administration, Oral; Adult; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Female; Hea | 1980 |
[Pseudo AV dissociation caused by interpolated junctional extrasystoles in the presence of a first-degree AV block].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Cardiac Complexes, Prematu | 1995 |
Cases in electrocardiography.
Topics: Atrial Fibrillation; Electrocardiography; Female; Humans; Middle Aged; Propafenone; Tachycardia, Par | 1995 |
Calcium channel blockers for heart rate control in atrial fibrillation complicated by congestive heart failure.
Topics: Atrial Fibrillation; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Female; Heart Fa | 1995 |
Verapamil or diltiazem for acute rate control: which is best.
Topics: Atrial Fibrillation; Atrial Flutter; Diltiazem; Heart Rate; Humans; Verapamil | 1995 |
Effects of verapamil on electrophysiological properties in paroxysmal atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Cardiac Pacing, Artificial; Electrocardiography; Heart Conduction System; | 1993 |
Preliminary investigation of the efficacy of sublingual verapamil in the management of acute atrial fibrillation and flutter.
Topics: Acute Disease; Administration, Sublingual; Aged; Atrial Fibrillation; Atrial Flutter; Chromatography | 1994 |
Effects of intravenous verapamil on atrial vulnerability.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Electrocardiography; Female; Heart | 1994 |
[Paroxysmal atrial fibrillation and flutter and "occult" arterial hypertension. The importance of the ambulatory monitoring of the blood pressure. Apropos 2 cases].
Topics: Atenolol; Atrial Fibrillation; Atrial Flutter; Blood Pressure Monitors; Diltiazem; Drug Therapy, Com | 1993 |
R56865 is antifibrillatory in reperfused ischemic guinea-pig hearts, even when given only during reperfusion.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzothiazoles; Calcium; Calcium Channel Block | 1995 |
Longitudinal clinical and electrophysiological assessment of patients with symptomatic Wolff-Parkinson-White syndrome and atrioventricular node reentrant tachycardia.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular N | 1996 |
Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1996 |
Verapamil-induced acute right heart failure.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function, Right; Cardia | 1996 |
New treatment of atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Calcium Channel Blockers; Digoxin; Diltiazem; Drug | 1996 |
Electrical remodeling in atrial fibrillation. Time course and mechanisms.
Topics: Animals; Atrial Fibrillation; Calcium; Calcium Channel Blockers; Cardiac Pacing, Artificial; Dogs; E | 1996 |
[Conversion rate and prevention of recurrence of paroxysmal and sustained atrial fibrillation or atrial flutter with verapamil/quinidine].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dose-Response Relationship | 1996 |
Verapamil reduces tachycardia-induced electrical remodeling of the atria.
Topics: Animals; Atrial Fibrillation; Calcium; Calcium Channel Blockers; Cardiac Pacing, Artificial; Goats; | 1997 |
[Torsade de pointes tachycardia during administration of quinidine and verapamil in atrial fibrillation].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Combinations; Electrocardiography; Fatal Out | 1997 |
Verapamil or diltiazem for acute rate control.
Topics: Atrial Fibrillation; Atrial Flutter; Cost-Benefit Analysis; Diltiazem; Heart Rate; Humans; Treatment | 1997 |
Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Cardiac Pacing, Artificial; Ele | 1997 |
Near doubling of heart rate after intravenous verapamil for treatment of atrial fibrillation without preexcitation.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; Hea | 1997 |
Physiology of the escape rhythm after radiofrequency atrioventricular junctional ablation.
Topics: Adenosine; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Atropine; Bundl | 1998 |
Rate control therapy for atrial fibrillation following coronary artery bypass surgery.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Dig | 1998 |
Atrial electrical remodeling by rapid pacing in the isolated rabbit heart: effects of Ca++ and K+ channel blockade.
Topics: 4-Aminopyridine; Action Potentials; Analysis of Variance; Animals; Atrial Fibrillation; Atrial Funct | 1998 |
Adenosine in the diagnosis of wide complex tachycardias.
Topics: Adenosine; Aged; Atrial Fibrillation; Coronary Disease; Diagnosis, Differential; Digoxin; Electrocar | 1994 |
Short-term effect of atrial fibrillation on atrial contractile function in humans.
Topics: Adult; Atrial Fibrillation; Atrial Function, Left; Atrial Function, Right; Calcium Channel Blockers; | 1999 |
Verapamil prolongs atrial fibrillation by evoking an intense sympathetic neurohumoral effect.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Catecholamines; Dogs | 1999 |
Postcardioversion atrial electrophysiologic changes induced by oral verapamil in patients with persistent atrial fibrillation.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Electric C | 2000 |
Profibrillatory effects of verapamil but not of digoxin in the goat model of atrial fibrillation.
Topics: Acute Disease; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Chr | 2000 |
Effects of simultaneous atrioventricular pacing on atrial refractoriness and atrial fibrillation inducibility: role of atrial mechanoelectrical feedback.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Atrioventricular Node; Autonomi | 2001 |
Verapamil prevents stretch-induced shortening of atrial effective refractory period in langendorff-perfused rabbit heart.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Calcium Channel Blockers; Car | 2001 |
Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Chronic Disease; Female; Heart Co | 1999 |
Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.
Topics: Animals; Atrial Fibrillation; Autonomic Nervous System; Calcium; Calcium Channel Blockers; Diltiazem | 2001 |
Increased dispersion and shortened refractoriness caused by verapamil in chronic atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Chronic Disease; Electrocardiography; Female; Heart Atria; Humans; Infusi | 2001 |
Altered values of heart rate variability in patients with relapse of atrial fibrillation during the first week after electrical cardioversion: preliminary data.
Topics: Aged; Amiodarone; Atrial Fibrillation; Circadian Rhythm; Electric Countershock; Electrocardiography, | 2001 |
Can short-term verapamil therapy reduce the recurrence of atrial fibrillation after successful low energy intracardiac cardioversion?
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function, Right; Calcium Channel Bl | 2001 |
[An elderly case of idiopathic dilatation of the right atrium in which right-sided heart failure was exacerbated by drug-induced bradyarrhythmia].
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Bradycardia; Cardiomegaly; Cardiotonic Agents; Dilatat | 2001 |
[Drug interaction behind the toxicity of chemotherapy].
Topics: Aged; Anti-Arrhythmia Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; C | 1998 |
[Atrial fibrillation successfully converted. A new standard in the prevention of recurrence?].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Calcium Ch | 2001 |
Effects of verapamil and ibutilide on atrial fibrillation and postfibrillation atrial refractoriness.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Chi-Square Distribut | 2002 |
Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agent | 2002 |
Patients with persistent atrial fibrillation taking oral verapamil exhibit a lower atrial frequency on the ECG.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Circadian Rhythm; Electroca | 2002 |
Daily oral verapamil before but not after rapid atrial excitation prevents electrical remodeling.
Topics: Action Potentials; Administration, Oral; Analysis of Variance; Animals; Atrial Fibrillation; Calcium | 2002 |
[Drug therapy of pre-excitation syndromes].
Topics: Adrenergic beta-Antagonists; Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrilla | 1977 |
The treatment of supraventricular arrhythmias.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Arrhyt | 1979 |
[Complications in the successive use of beta-adrenoblockaders and izoptin].
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Female; Heart Block; Humans; Middle Aged; Tachycar | 1979 |
[Experience with the use of izoptina].
Topics: Angina Pectoris; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Follow-Up | 1975 |
[Four years of clinical experience with the cardio-eurhythmic action of verapamil in intravenous administration].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Complexes, Premature; Injections, | 1975 |
[Drug therapy of tachycardial heart-rhythm disorders].
Topics: Adrenergic beta-Antagonists; Ajmaline; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; | 1976 |
[Verapamil in the study and treatment of supraventricular tachycardias, with special reference to pre-excitation].
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Atrioventricular Node; Calcium; Drug Therapy, Comb | 1975 |
[Verapamil in the treatment of arrhythmias after open-heart surgical operations].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures; Humans; Post | 1978 |
Paroxysmal nonreentrant tachycardias due to simultaneous conduction in dual atrioventricular nodal pathways.
Topics: Adult; Ajmaline; Atrial Fibrillation; Atrioventricular Node; Atropine; Bundle of His; Cardiac Pacing | 1979 |
Verapamil-induced ventricular regularity in atrial fibrillation. Effects of exercise, isoproterenol, atropine and conversion to sinus rhythm.
Topics: Adult; Aged; Atrial Fibrillation; Atropine; Electrocardiography; Exercise Test; Female; Heart Rate; | 1979 |
The beneficial effects of verapamil in chronic atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Chronic Disease; Digoxin; Female; Heart Rate; Humans; Male; Middle Aged; | 1979 |
[Effect of isoptin in auricular fibrillation in a patient with Wolff-Parkinson-White syndrome].
Topics: Adult; Atrial Fibrillation; Atrioventricular Node; Electrocardiography; Female; Humans; Tachycardia; | 1979 |
Verapamil for atrial flutter/fib.
Topics: Atrial Fibrillation; Humans; Verapamil | 1979 |
Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Female; Heart Rate; Humans; Male; Middle Aged; Ver | 1979 |
[A comparison of rohdealine and verapamil in the treatment of supraventricular cardiac arrhythmias].
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Cardiac Glycosides; Female; Humans; Male; Middle Aged; | 1979 |
Acute antiarrhythmic effects of intravenous verapamil (Isoptin) in supraventricular tachy-arrhythmias.
Topics: Adolescent; Adult; Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Child; Dogs; Female; Humans; | 1977 |
Oral verapamil as maintenance therapy after cardioversion for atrial fibrillation.
Topics: Adolescent; Adult; Atrial Fibrillation; Electric Countershock; Female; Humans; Male; Middle Aged; Re | 1977 |
[Re-evaluation of the use of verapamil in supraventricular tachyarrhythmias].
Topics: Atrial Fibrillation; Atrial Flutter; Electrocardiography; Humans; Tachycardia; Ventricular Fibrillat | 1978 |
[Verapamil associated with quinidine in the treatment of chronic atrial fibrillation].
Topics: Adult; Aged; Atrial Fibrillation; Chronic Disease; Drug Therapy, Combination; Female; Humans; Male; | 1978 |
[Drug-induced conversion of arterial fibrillation/flutter by a verapamil/quinidine combination].
Topics: Atrial Fibrillation; Atrial Flutter; Drug Therapy, Combination; Humans; Quinidine; Verapamil | 1978 |
Plasma digoxin concentrations in patients with atrial fibrillation and indications for the association with other antiarrhythmic agents.
Topics: Aged; Atrial Fibrillation; Digoxin; Drug Interactions; Drug Therapy, Combination; Female; Heart Rate | 1977 |
[Drug therapy of tachycardial arrhythmias].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digitalis Glycosides; Drug Therapy, Combina | 1976 |
Atrial activity in atrial fibrillation after intravenous verapamil.
Topics: Aged; Atrial Fibrillation; Female; Heart Atria; Heart Rate; Humans; Injections, Intravenous; Male; M | 1976 |
Haemodynamic effect of intravenous verapamil in controlled atrial fibrillation.
Topics: Adult; Atrial Fibrillation; Blood Pressure; Cardiac Output; Electrocardiography; Female; Heart Rate; | 1975 |
[Venous infusion of nerapamil in the treatment of refractory angina pectoris and arrhythmia due to associated electric instability].
Topics: Adult; Angina Pectoris; Angiography; Arrhythmias, Cardiac; Atrial Fibrillation; Coronary Angiography | 1975 |
[Clinical results with verapamil in intravenous administration in the emergency therapy of cardiac arrhythmias].
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Coronary Disease; Female; Heart | 1975 |
[Anti-arrhythmic therapy with verapamil by intravenous infusion].
Topics: Adolescent; Adult; Aged; Angina Pectoris; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; | 1975 |
Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Blood Pressure; | 1975 |
Clinical experience with verapamil.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Heart Block; Heart C | 1975 |
[Treatment of heart-rhythm disorders in infancy and childhood].
Topics: Age Factors; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Chil | 1975 |
[Sudden and transient fibrillations of the auricle].
Topics: Aged; Atrial Fibrillation; Electrocardiography; Female; Humans; Male; Middle Aged; Time Factors; Ver | 1976 |
[Tachycardiomyopathy induced by atrial fibrillation].
Topics: Atrial Fibrillation; Atrioventricular Node; Female; Heart Rate; Humans; Hypertrophy, Left Ventricula | 1992 |
[Clinical effectiveness of cordarone in combination with other anti-arrhythmia agents in refractory atrial fibrillation and adverse effects of the drugs].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Drug Therapy, Combina | 1992 |
[The chronotropic and hemodynamic effects of finoptin in patients with a permanent form of atrial fibrillation].
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Chronic Disease; Digoxin; Drug Evaluation; Drug | 1992 |
[A paroxysm of atrial flutter-fibrillation simulating ventricular tachycardia].
Topics: Acute Disease; Adenosine Triphosphate; Aged; Atrial Fibrillation; Atrial Flutter; Diagnosis, Differe | 1992 |
[Clinical efficacy of combined therapy with verapamil and fast sodium channel blockers for refractory atrial fibrillation].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Humans; Middle | 1991 |
[Electrophysiological effect of verapamil on human atrium].
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Electrophysiology; Female; Heart Atria; Humans; Male; | 1991 |
Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Chronic Disease; Digoxin; Exercise; Heart Rate; Humans; Male; Middle Aged | 1991 |
Calcium channel blockers.
Topics: Aged; Atrial Fibrillation; Bipolar Disorder; Combined Modality Therapy; Electroconvulsive Therapy; H | 1990 |
[Torsade de pointes induced by quinidine: a case treated successfully with verapamil].
Topics: Adult; Atrial Fibrillation; Electrocardiography; Humans; Quinidine; Torsades de Pointes; Verapamil | 1990 |
Emergency department management of patients with automatic implantable cardioverter-defibrillators.
Topics: Atrial Fibrillation; Cardiomyopathy, Dilated; Electric Countershock; Electrocardiography; Emergencie | 1990 |
Short-term control of supraventricular tachycardia with verapamil infusion and calcium pretreatment.
Topics: Aged; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Calcium; Female; Heart Rate; Humans; Infu | 1990 |
Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation.
Topics: Adult; Atrial Fibrillation; Electrocardiography; Humans; Injections, Intravenous; Male; Verapamil; W | 1989 |
[Supraventricular tachyarrhythmia of recent onset in the absence of documented cardiac pathology: different therapeutic approaches].
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Electric Countershock; | 1989 |
Misuse of verapamil in pre-excited atrial fibrillation.
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Diagnostic Errors; Emergencies; Female; Heart Ventricl | 1989 |
Degeneration of junctional tachycardia to pre-excited atrial fibrillation after intravenous verapamil.
Topics: Adult; Atrial Fibrillation; Electrocardiography; Female; Humans; Injections, Intravenous; Tachycardi | 1989 |
[Anaphylactic shock after i.v. verapamil].
Topics: Adrenal Cortex Hormones; Anaphylaxis; Atrial Fibrillation; Female; Histamine H1 Antagonists; Humans; | 1989 |
[Arrhythmias in hypertrophic cardiomyopathy. Significance and therapeutic consequences].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Pr | 1985 |
[Pharmacologic restoration of sinus rhythm in atrial flutter and fibrillation].
Topics: Atrial Fibrillation; Atrial Flutter; Digoxin; Drug Therapy, Combination; Female; Heart Rate; Humans; | 1989 |
[Wolff-Parkinson-White syndrome and verapamil: apropos of a case of ventricular fibrillation].
Topics: Adult; Atrial Fibrillation; Electrocardiography; Female; Humans; Ventricular Fibrillation; Verapamil | 1989 |
[Combination of quinidine and verapamil in auricular fibrillation].
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Drug Evaluation; Drug Therapy, Combination; | 1989 |
[Intravenous therapy with verapamil in patients receiving permanent treatment with oral beta-blockers].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atrial Fibrillation; Drug Therapy, Combination; Female; Hu | 1985 |
Hyperthyroid-induced atrial flutter-fibrillation with profound sinoatrial nodal pauses due to small doses of digoxin, verapamil, and propranolol.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Digoxin; Female; Humans; Hyperthyroidism; | 1989 |
Augmented fragmentation of atrial activity upon premature electrical stimuli by verapamil.
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Cardiac Pacing, Artificial; Electrocardiography; Elect | 1989 |
The effect of drugs and lead maturation on atrial electrograms during sinus rhythm and atrial fibrillation.
Topics: Algorithms; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Dogs; | 1989 |
Pindolol, not verapamil, in combination with digoxin is the treatment of choice in chronic atrial fibrillation.
Topics: Atrial Fibrillation; Chronic Disease; Digoxin; Drug Therapy, Combination; Humans; Pindolol; Verapami | 1989 |
[Pharmacological cardioversion of paroxysmal atrial fibrillation: 3 methods compared].
Topics: Aged; Amiodarone; Atrial Fibrillation; Deslanoside; Drug Evaluation; Drug Therapy, Combination; Elec | 1987 |
Verapamil in atrial fibrillation in hyperthyroidism.
Topics: Aged; Atrial Fibrillation; Female; Humans; Hyperthyroidism; Male; Middle Aged; Verapamil | 1987 |
Comparative efficacy of Univer and conventional verapamil in the control of ventricular response in atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Delayed-Action Preparations; Digoxin; Drug Therapy, Combination; Female; | 1988 |
Verapamil-induced atrial fibrillation.
Topics: Adult; Atrial Fibrillation; Humans; Male; Verapamil | 1988 |
[Verapamil in the treatment of atrial fibrillation in patients with thyrotoxicosis].
Topics: Aged; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Thyrotoxicosis; Verapamil | 1988 |
[Treatment of recently developed atrial fibrillation using a combination of Kinilentin and Isoptin].
Topics: Adult; Atrial Fibrillation; Drug Therapy, Combination; Female; Heart Valves; Humans; Male; Postopera | 1988 |
Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation.
Topics: Administration, Oral; Adult; Atrial Fibrillation; Blood Pressure; Calcium Channel Blockers; Diltiaze | 1988 |
Sustained atrial fibrillation after conversion of paroxysmal reciprocating junctional tachycardia by intravenous verapamil.
Topics: Aged; Atrial Fibrillation; Cardiac Pacing, Artificial; Electrocardiography; Electrophysiology; Human | 1988 |
24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation.
Topics: Adult; Aged; Atrial Fibrillation; Chronic Disease; Delayed-Action Preparations; Drug Administration | 1987 |
Differential effect of some antiarrhythmic drugs in right- or left-sided aconitine-induced experimental atrial arrhythmias.
Topics: Aconitine; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dogs; Female; Male; | 1987 |
Haemodynamic disturbances during anaesthesia in a patient receiving verapamil.
Topics: Aged; Anesthesia, General; Atrial Fibrillation; Cataract Extraction; Humans; Hypotension; Intraopera | 1987 |
[A-V block secondary to cimetidine-verapamil interaction].
Topics: Adult; Atrial Fibrillation; Cimetidine; Drug Interactions; Heart Block; Humans; Male; Verapamil | 1987 |
Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Heart Arrest; H | 1986 |
Treatment of atrial arrhythmias. Effectiveness of verapamil when preceded by calcium infusion.
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Atrial Flutter; Calcium Chloride; Digoxin; Drug Evalua | 1986 |
Supraventricular tachycardia emergencies: diagnosis and management.
Topics: Atrial Fibrillation; Atrial Flutter; Digitalis; Electrocardiography; Electrophysiology; Emergencies; | 1986 |
Effectiveness of oral verapamil in controlling ventricular rate in patients with chronic atrial fibrillation receiving digoxin.
Topics: Adolescent; Adult; Atrial Fibrillation; Chronic Disease; Digoxin; Drug Therapy, Combination; Female; | 1986 |
[Effects of verapamil in atrial fibrillation].
Topics: Atrial Fibrillation; Electrocardiography; Heart Rate; Humans; Myocardial Contraction; Verapamil | 1985 |
Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy.
Topics: Adolescent; Atrial Fibrillation; Cardiac Catheterization; Cardiac Pacing, Artificial; Cardiomyopathy | 1986 |
Fatal ventricular fibrillation following verapamil in Wolff-Parkinson-White syndrome with atrial fibrillation.
Topics: Adult; Atrial Fibrillation; Humans; Male; Verapamil; Wolff-Parkinson-White Syndrome | 1985 |
Supraventricular tachycardias in the emergency room.
Topics: Atrial Fibrillation; Atrial Flutter; Digoxin; Edrophonium; Electric Countershock; Emergencies; Human | 1985 |
Atrial fibrillation in the Wolff-Parkinson-White syndrome: effects of verapamil and procainamide.
Topics: Atrial Fibrillation; Drug Therapy, Combination; Electrocardiography; Humans; Male; Middle Aged; Proc | 1985 |
Efficacy of disopyramide in comparison with verapamil and propranolol in the prevention of acetylcholine-induced atrial fibrillation in the dog.
Topics: Acetylcholine; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressu | 1985 |
Adverse effects of atrial fibrillation and syncope induced by calcium-channel blockers in hypertrophic cardiomyopathy.
Topics: Adult; Atrial Fibrillation; Benzazepines; Cardiomyopathy, Hypertrophic; Diltiazem; Echocardiography; | 1985 |
[State of blood digoxin after acute simultaneous administration of digoxin and verapamil].
Topics: Atrial Fibrillation; Digoxin; Drug Therapy, Combination; Humans; Radioimmunoassay; Verapamil | 1985 |
[Arrhythmias in the elderly patients: atrial fibrillation].
Topics: Aged; Aging; Atrial Fibrillation; Coronary Disease; Diltiazem; Humans; Hypertension; Mitral Valve In | 1985 |
[Ventricular fibrillation as a result of digoxin and verapamil interaction].
Topics: Atrial Fibrillation; Digoxin; Drug Synergism; Drug Therapy, Combination; Female; Humans; Middle Aged | 1985 |
[What is assured in the treatment of heart arrhythmia?].
Topics: Adrenergic beta-Antagonists; Ajmaline; Atrial Fibrillation; Atrial Flutter; Atropine; Bradycardia; C | 1972 |
Clinical effects of verapamil in cardiac arrhythmias.
Topics: Adult; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Complexes, Premature; Fema | 1972 |
[Therapy of arrhythmias].
Topics: Ajmaline; Arrhythmias, Cardiac; Atrial Fibrillation; Bradycardia; Caffeine; Cardiac Complexes, Prema | 1973 |
[The treatment of cardiac arrhythmias: complexity and schematization].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atri | 1973 |
[Effect of anti-arrhythmic drugs on intracardiac conduction (His-bundle electrogram) and sinus-node automatism in man].
Topics: Acetanilides; Adrenergic beta-Antagonists; Ajmaline; Amino Alcohols; Anti-Arrhythmia Agents; Atrial | 1973 |
[The treatment of heart arrhythmia with the heart sympatholytic iproveratril].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Com | 1967 |
[Treatment of heart rhythm disorders with beta-receptor-blocking agents].
Topics: Anti-Arrhythmia Agents; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter | 1968 |
[Use of isoptin in angina pectoris and heart rhythm disorders].
Topics: Adolescent; Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibri | 1967 |
[Drug therapy of tachycardiac arrhythmias].
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillatio | 1969 |
Verapamil in life-threatening tachyarrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Output; Electrocardiography; Emer | 1972 |
[Combined treatment of auricular fibrillation and other tachycardiac arrhythmias using quinidine and verapamil].
Topics: Adult; Aged; Atrial Fibrillation; Drug Combinations; Female; Humans; Male; Middle Aged; Quinidine; T | 1972 |
The use of intravenous verapamil in cardiac arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Humans; Injections, Intraven | 1973 |
[Interval histograms of ventricular frequency in auricular fibrillation following Verpamil (Isoptin) medication].
Topics: Atrial Fibrillation; Electrocardiography; Humans; Verapamil | 1973 |
Concealed bypasses of the atrioventricular mode in patients with paroxysmal supraventricular tachycardia revealed by intracardiac electrical stimulation and verapamil.
Topics: Adult; Aged; Atrial Fibrillation; Coronary Disease; Electrocardiography; Female; Heart Conduction Sy | 1974 |
Immediate effects of intravenous verapamil in cardiac arrhythmias.
Topics: Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Electrocardiography; Female; Humans | 1972 |
Mode of action of verapamil in man.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Heart Conduction System; Humans; Verapamil | 1972 |
[Clinical analysis of the antiarrhythmic effect of Verapamils].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Drug Antagonism; | 1972 |
Hypotension after verapamil.
Topics: Atrial Fibrillation; Humans; Hypotension; Male; Middle Aged; Verapamil | 1972 |
[Trials of auricular defibrillation with the quinidine-verapamil combination by oral route].
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Evaluation Studies as Topic; Female; Humans; | 1972 |
An antidysrhythmic agent.
Topics: Atrial Fibrillation; Electric Countershock; Female; Humans; Middle Aged; Tachycardia, Paroxysmal; Ve | 1971 |
[The antiarrhythmic action mechanism of verapamil (Isoptin)].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Atropine; Blood Pressure; Drug Antagonism | 1971 |
Immediate effects of intravenous verapamil on atrial fibrillation.
Topics: Adult; Aged; Analysis of Variance; Arteriosclerosis; Atrial Fibrillation; Depression, Chemical; Elec | 1971 |
The mechanism of action of verapamil on the sinus and AV nodes.
Topics: Acetylcholine; Animals; Anti-Arrhythmia Agents; Arteries; Atrial Fibrillation; Blood Flow Velocity; | 1969 |
[Late results of treating auricular flutter and fibrillation using controlled cardiac phasic electroshock].
Topics: Atrial Fibrillation; Atrial Flutter; Cardiac Glycosides; Electric Countershock; Humans; Premedicatio | 1971 |
[Treatment of tachycardiac disorders of the heart rhythm by beta-receptor block of the atrioventricular tissue].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Humans; Male; | 1966 |